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ABSTRACT 
 
 At least two specific features differentiate bone from other tissues, a 
blend of organic and mineral components, and a cellular organization with a 
hierarchical commitment degree. During bone remodeling osteoclasts dissolve 
the mineral and degrade the organic bone components, releasing the 
degradation products to the extracellular space. 
 Bone is the hardest connective tissue in the human body. However, 
skeletal tissue can be injured by trauma, atrophied by tooth loss, destroyed by 
pathological conditions or incompletely formed during congenital craniofacial 
bone defects, such as cleft palate. Autogenous bone is considered the “gold 
standard” to regenerate bone defects. However, wherever bone is harvested 
undesirable and detrimental effects are produced at the donor area. To avoid 
these drawbacks, bone tissue engineering has emerged to provide an 
alternative to autogenous bone harvesting drawbacks. It has been shown by 
several “in vitro” an “in vivo” studies that BMP-2 promotes osteogenic 
differentiation and bone formation. High doses are required (e.g. 1-45 g/ml in 
animal models) to obtain acceptable outcomes. However, several side effects, 
such as inflammation and ectopic bone formation, have been reported after 
using elevated amounts of BMP-2.   
 In this work we employed a composite Gelatin/CaSO4 scaffold that 
allows for an early expansion of seeded MSC´s, which is followed by an 
increased level of osteogenic differentiation after 10 days in culture. 
Furthermore, this seeded scaffold enhanced bone formation in a mouse model 
of critical-size calvarial defects. More importantly, ex vivo pretreatment of 
MSC´s with low amounts of BMP-2 (2nM) and Wnt3a (50 ng/ml) for 24 hours 
cooperatively increases the expression of osteogenic markers in vitro and bone 
regeneration in the critical-size calvarial defect in the mouse model. 
 viii
 Moreover, we determined the molecular mechanisms involved in 
cooperation between Ca2+ and BMP-2 in MSC´s at early and late differentiating 
points. Early, at 24 hours, we observed an intracellular network activation which 
is antagonistic to BMP-2/Smad signalling. More importantly, a significant 
cooperative effect between Ca2+ and BMP-2 is observed after 10 days. Ca2+ 
promotes an autocrine/paracrine feed-forward loop that reinforces the BMP-2 
osteogenic input. Of note, Ca2+ alone induced similar osteogenic effects as 
BMP-2 alone in long-term cell culture. 
 In conclusion, cytokine signalling (such as BMP-2) and signalling from 
the mineral component (such as Ca2+) signals interact during bone remodeling. 
Early on, Ca2+ inhibits BMP-2 differentiation effect but later amplifies and 
reinforces the osteogenic BMP-2 effect.  
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RESUMEN 
 
 Al menos dos características distinguen al hueso de otros tejidos, es un 
compuesto con elementos orgánicos y minerales y además tiene una 
organización celular con diferentes niveles de diferenciación. Durante el 
remodelado óseo los osteoclastos disuelven el componente mineral y degradan 
la fase orgánica liberando sus productos de degradación hacia el espacio 
extracelular. 
 El hueso es el tejido conectivo con mayor dureza en el cuerpo humano. 
Sin embargo, el tejido óseo puede ser dañado después de un trauma, puede 
sufrir atrofia por la pérdida de dientes, podría ser destruido por condiciones 
patológicas o incompletamente formado durante defectos óseos craniofaciales 
congénitos, tal como el paladar hendido. El hueso autólogo ha sido considerado 
la mejor alternativa para regenerar defectos óseos. Sin embargo, de cualquier 
sitio de donde se obtenga produce morbilidad en la zona donante. Para evitar 
esa desventaja, la ingeniería de tejido óseo ha surgido como una alternativa al 
hueso autólogo.  Ha sido demostrado  por estudios in vitro e in vivo que BMP-2  
favorece la diferenciación de osteoblastos y la formación ósea. Altas dosis son 
necesarias (por ejemplo 1-45 g/ml) para obtener resultados aceptables. Sin 
embargo, varios efectos adversos tal como inflamación y formación ectópica de 
hueso han sido publicados después de usar elevadas dosis de BMP-2. 
 En este trabajo hemos utilizado una combinación de Gelatina/CaSO4 
como andamiaje para cultivar células madre mesenquimales (MSC´s). Este 
andamiaje promueve inicialmente una amplificación de las células cultivadas, lo 
cual es seguido por una mayor diferenciación osteoblástica después de 10 días 
de cultivo. Además, este andamiaje cultivado con MSC´s incrementó la 
formación de hueso en un defecto óseo de tamaño crítico en cráneo de ratón. 
Lo más notable, pretratamiento de MSC´s “ex vivo” con dosis bajas de BMP-2 
 x
(2nM) y Wnt3a (50 ng/ml) durante 24 horas incrementó cooperativamente la 
expresión de marcadores osteogénicos “in vitro” y la regeneración ósea en los 
defectos de tamaño critico en cráneo de ratón. 
 Además, determinamos el mecanismo molecular involucrado en la 
cooperación entre Ca2+ y BMP-2   a corto y largo término durante la secuencia 
de diferenciación de las MSC´s en osteoblastos. Al inicio a las 24 horas, 
observamos la activación de una red de señalización intracelular la cual es 
antagónica  a la vía BMP-2/Smad. A los 10 días, un efecto cooperativo entre 
Ca2+ y BMP-2 es observado. Ca2+ promueve la secreción endógena  de BMP-2 
lo cual produce un efecto autocrino y paracrino que refuerza  la acción 
osteogénica  inicial de BMP-2. Notablemente, un efecto similar en la 
diferenciación osteoblástica fue observado en MSC´s  tratadas únicamente con 
Ca2+ comparado con las tratadas solo con BMP-2.  
 En conclusión, señalización por citoquinas como  BMP-2 y Ca2+ 
(componente mineral) interactúan  durante el remodelado óseo. Ca2+ regula el 
estímulo osteogénico de BMP-2 mediante un mecanismo secuencial. 
Inicialmente, Ca2+ inhibe la diferenciación celular producida por BMP-2  pero 
después de 10 días amplifica y refuerza el efecto osteogénico de BMP-2 
favoreciendo la diferenciación de osteoblastos y la formación ósea. 
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1. CHAPTER I: INTRODUCTION 
 
  
 
 
  2
1.1 BONE BIOCHEMICAL COMPOSITION AND CELLULAR ORGANIZATION 
 
 At least two specific features differentiate bone from other tissues, a 
particular arrangement of organic and mineral components and a cellular 
organization with a hierarchical commitment degree. This living biocomposite 
with a particular structure, composition and cellular disposition provide the 
skeleton with singular regenerative, mechanical and metabolic characteristics. 
In addition, the skeletal tissue allows a protective function of vital structures in 
thorax and in cranium. 
 
1.1.1 Bone as biomaterial 
 Bone is a heterogeneous composite material consisting in decreasing 
order, of a mineral phase 65% (hydroxyapatite), an organic phase 25 % 
(collagen 90%, non- collagen proteins 5-10% and lipids 2%) and water 10% 
(Olszta, Cheng et al. 2007, Boskey 2013). Bone is commonly considered as a 
biphasic structure. A biocomposite with a mineral and an organic components. 
The bone mineral has been idealized as calcium hydroxyapatite, Ca10(PO4)6 
(OH2)2 (Kay, Young et al. 1964). However, biologic apatites contain minor and 
trace elements. The most important minor elements are carbonate (CO3), 
magnesium (Mg) and sodium (Na) (LeGeros 2008). Indeed, approximately 99% 
of body calcium, 85% of the phosphorus, and between 40-60% of total body 
sodium and magnesium are associated with bone crystals (Buckwalter M. J. 
Glimcher et al 1995).The organic phase corresponds mostly to collagen Type I 
and to a lesser degree to non-collagenous proteins. This latter fraction is 
composed by osteocalcin, osteonectin, bone sialoprotein, osteopontin and 
growth factors such as TGFβ, IGF, FGF, BMP, VEGF and PDGF (Buckwalter M. 
J. Glimcher et al 1995, Linkhart, Mohan et al. 1996).Therefore, individually each 
bone component could act as relevant local biochemical signals for bone cells.  
 Bone can be depicted as a combination of a rigid inorganic component 
with a flexible collagen organic matrix. In this biocomposite the mineral provides 
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stiffness and strength to the bone tissue, whereas the collagen provides ductility 
or flexibility (Wilson, Awonusi et al. 2005). The small amounts of lipids, such as 
fatty acids, cholesterol, phospholipids, contained  in mineralized bone tissue 
itself might play an important role in bone cell survival, critical signalling 
molecules and biomineralization (During, Penel et al. 2015).  In addition, water 
may serve to couple the mineral to the organic matrix and may play a role in 
deformation (Wilson, Awonusi et al. 2005). With aging, there is a marked decline 
in the content of water (Triffitt, Terepka et al. 1968) and the mechanical 
behavior, morphology, bone cells, the matrix they produce and mineral 
deposited on this matrix are modified (Boskey and Coleman 2010). Therefore, 
the relative amounts and properties of the mineral and organic matrix in bone, 
as well as the organization at both the microscopic and macroscopic scales 
determine its mechanical strength (Boskey, Wright et al. 1999). A trabecular 
bone model as a nanocomposite material with hierarchical structure has been 
suggested. The model involves a bottom-up multi-scale approach, starting with 
nanoscale (mineralized collagen fibril) and moving up the scales to mesoscale 
(trabecular bone) levels (Hamed, Jasiuk et al. 2012).Figure 1.1. 
 
 
Figure 1.1.Simplified bone composition and hierarchical structure of trabecular bone. 
Taken from (Hamed, Jasiuk et al. 2012) 
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1.1.2 Anatomical cellular relationship between bone and bone marrow. 
 Bone marrow and trabecular bone are closely related. Wherever true 
bone is formed, irrespective of the initiating mechanism, it generally leads to 
new hematopoietic marrow (Triffitt 1987). They are adjacent tissues changing 
gradually without a clear separation as a whole anatomical structure, but each 
one with different and specific functions. The bone marrow can be seen as two 
mayor compartments, the stroma and the hematopoietic. Figure 1.2. 
 
 
 
Figure 1.2. Bone and bone marrow cells relationship. Taken from (Bonomo, Monteiro et 
al. 2016) 
 
 Anatomically, bone marrow stroma includes all non-hematopoietic 
reticular cells, adipocytes, endothelial cells, macrophages and osteoblasts 
(Weiss 1976, Balduino, Hurtado et al. 2005, Krause, Scadden et al. 2013). The 
stroma of marrow consists mainly of a network of reticular cells and fibers 
together with the endothelial cells lining the walls of the sinusoidal vessels 
(Owen 1980). The parenchyme is composed of all the different immature and 
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mature blood cell precursors (Fliedner, Graessle et al. 2002). Stromal derived 
mesenchymal stem cells can, under suitable conditions, differentiate into 
osteoblasts, whereas the bone resorbing osteoclasts arise from the 
hematopoietic fraction.  
 By morphological/histochemical criteria and proliferative ability five 
maturational stages in osteoblast lineage could been identified: skeletal 
progenitors, preosteoblasts, osteoblasts, osteocytes and bone lining cells (BLC) 
(Aubin 1998, Bianco 2011). Osteoblasts in trabecular bone are derived from 
mesenchymal stem cells present in bone marrow stroma. These cells with bone 
forming potential localized in marrow can be divided in two groups. First, those 
which are capable of spontaneous differentiation and have been called 
determined osteogenic precursor cells (DOPC) (Owen 1978). Second, 
undifferentiated mesenchymal cells which will form bone in the presence of an 
inducing agent, they are called inducible osteogenic precursor cells (IOPC) 
(Owen 1978). Inductive agents such as decalcified bone matrix, transitional 
epithelium of the bladder and bone morphogenetic proteins (BMP´s) have been 
reported (Friedenstein 1968, Huggins 1968, Urist and Strates 1971). DOPC 
have been shown to be present only in the stromal tissue of marrow and bone 
surfaces, whereas IOPC are found widespread throughout many connective 
tissues and in marrow (Owen 1980).  
 Associated with this, it has been reported that the endosteal/ 
subendosteal environment comprise two distinct stroma-cell populations, 
subendosteal reticulocytes (F-RET) and osteoblast (F-OST). Balduino and 
Hurtado et al. (2005) found that F-OST cells cultured in standard culture 
medium spontaneously formed extensive mineralized nodules, whereas F-RET 
did not. The authors suggest that F-RET cells are mostly osteoprogenitor cells 
and F-OST represent a population of osteoblasts. 
 The preosteoblast is considered the immediate precursor of the 
osteoblast and is identified by its localization in the adjacent one or two cell 
layer from the osteoblasts lining bone formation surfaces (Aubin 1998). The 
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osteoblast is a specialized cell that produce bone by secreting an organic 
extracellular matrix which becomes a mineralized tissue. The percentage of 
trabecular bone surface covered by osteoblasts comprise around a 5%, but a 
gradual reduction is observed with age in samples of human cancellous bone 
from the iliac crest (Merz and Schenk 1970). Expressing Osteocalcin, Osterix 
and Runx, mature osteoblasts line the bone surface meanwhile an 
undifferentiated stromal subpopulation preferentially reside close to and around 
the sinusoidal wall in the subendosteal region (Nakamura, Arai et al. 2010, 
Cordeiro-Spinetti, Taichman et al. 2015). Figure 1.3. 
 
 
Figure 1.3.Mature osteoblastic cells line the bone surface, whereas mesenchymal 
osteoprogenitor cells reside around bone marrow microvessels. Taken from (Morrison 
and Scadden 2014) 
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 Osteoblasts trapped by the secreted extracellular matrix become 
osteocytes. This transformation involves a range of morphological changes such 
as decrease in cell body size, increase of cell processes and change in 
intracellular organelles  (Franz-Odendaal, Hall et al. 2006). Osteocytes form an 
intricate network of cytoplasmic prolongations interacting with one another and 
with those cells covering the bone surface. Osteocytes compose 90 to 95% of 
all bone cells in adult bone (Bonewald 2011) and they are considered the most 
differentiated cells in the osteoblast lineage.   
 About 75% of the surface of cancellous bone is quiescent (Parfitt 2003) 
and is covered by bone lining cells (BLC). These cells in the outer surface 
undergo a morphological change from a cuboidal to an “inactive” flattened 
shape. BLC separate the bone surface from the bone marrow. However, the 
mineralized bone surface is not in contact with the bone lining cells directly. 
They are separated from each other by the Lamina Limitans, a layer always 
present in “inactive” bone surfaces. The BLC layer forms an essential ionic 
partition between a bone fluid compartment, which includes the lacunae and 
their canaliculi, and an extracellular fluid compartment which includes the 
marrow and vascular space  (Menton, Simmons et al. 1984). 
 
1.1.3 Endosteum a frontier between bone and bone marrow 
 Although osteoblast, preosteoblast and postosteoblast stages can be 
identified, together they constitute an anatomically and physiologically linked 
system. The organization of bone from Lamina Limitans, endosteal bone lining 
cells to periendothelial mesenchymal stem cells in bone marrow maintain a 
functional connection. At the peritrabecular region the endosteum is placed as a 
border between the bone and bone marrow (Nakamura, Arai et al. 2010). 
Endosteal region is an enriched region in microvessels. Endosteum is the site in 
which a rich anastomotic network connects the bone and marrow circulation, 
which may contribute to defining a specific ionic environment at this site (Bianco 
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2011). A characteristic of the endosteum where active bone remodeling takes 
place is an increased extracellular calcium ion concentration (Adams, Chabner 
et al. 2006). 
 Four zones relative to endosteal surfaces and the wall or the central 
venous sinus have been suggested: endosteal, subendosteal, central and 
intermediate zones (Lambertsen and Weiss 1984). Figure 1.4. The endosteal 
and subendosteal zones compose the endosteal niche, where at least three 
stromal cell types can be identified: osteoblast, non-perivascular reticular cells 
(probably most pre osteoblasts) and perivascular cells, probably mesenchymal 
stem cells (Cordeiro-Spinetti, Taichman et al. 2015). 
 
 
Figure 1.4. Model of bone and bone marrow zones. Taken from (Lambertsen and Weiss 
1984) 
 
1.1.4 Bone remodeling 
 Bone remodeling is a temporal and localized renewal of damaged or 
aging bone. Figure 1.5. This bone replacement mechanism is made by 
coordinated and sequential actions of bone resorting osteoclasts and bone 
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forming osteoblasts. Although both osteoclast and osteoblast activity could be 
considered as isolated or disconnected events, they are interdependent actions. 
Both represent events within the same process carried out at the same location, 
the eroded bone surface.  
 Under physiological conditions, bone remodeling is a tightly regulated 
sequence of cellular events in response to physical and biochemical signals. 
Osteocytes and their canalicular network provide a mecanosensory detection 
system by which the bone remodeling sequence is not an aleatory process. 
Consequently, bone remodeling takes place only where it is needed in response 
to damage, to change in loading or to remove old bone (Sims and Martin 2014). 
The normal trabecular bone remodeling sequence can be represented by 
successive stages: quiescence, activation, resorption, reversal, formation and 
back to quiescence or termination (Parfitt 1984, Parfitt 1994, Rucci 2008, 
Raggatt and Partridge 2010). 
 A site where the bone surface is quiescent with respect to remodeling, 
meaning a resting region where neither resorption nor formation is currently in 
progress, is selected for initiating the process (Parfitt 1994). Osteocyte death by 
microdamage has been suggested to be the major event leading in the initiation 
of osteoclastic bone resorption (Eriksen 2010). Before osteoclast activation, the 
cement line or Lamina Limitants is degradated by osteoblastic lining cells in 
response to osteocyte signalling. This event produces a detachment between 
bone lining cells and the bone surface. This separation forms a specialized 
micro anatomical structure called Bone Remodeling Compartment (BRC) 
(Hauge, Qvesel et al. 2001). 
 
1.1.4.1 Osteoclasts degrade the mineral and organic bone components 
 Osteoclasts are multinucleated cells derived from circulating monocyte 
progenitors. They are specialized cells that remove damaged or aged bone. 
Quiescent or resting bone surfaces are covered by the Lamina Limitans which 
BLC must digest before osteoclasts degrade bone. 
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Figure 1.5. Bone remodeling is a temporal and localized cellular event. Taken from 
(Croucher, McDonald et al. 2016) 
 
 
 BLC predispose the bone surface to osteoclast resorption by exposing 
the mineral component of bone (Chambers and Fuller 1985). This mineral 
exposure promotes osteoclasts’ attachment to the denuded bone surface by 
forming a sealed zone. Osteoclasts dissolve the mineral portion of bone by acid 
production while the organic component is degradated partially by proteolytic 
activity. Acidic conditions are created by hydrochloric acid (HCl) secretion by 
osteoclasts releasing calcium, phosphate and water from the basic 
hydroxyapatite that comprises bone mineral (Blair 1998). Figure 1.6. 
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Figure 1.6. Osteoclast release bone degradation products by transcytosis toward the 
extracellular space.  Taken from (Takahashi, Udagawa et al. 2014) 
 
 
  The mineral phase is solubilized before collagen degradation (Bonucci 
1974, Blair, Kahn et al. 1986). Collagen fragments are produced and released 
by a partial degradation of the organic component. In addition, this incomplete 
breakdown leaves behind demineralized collagen bundles covering the 
resorption site walls after osteoclasts leave. Both, mineral (calcium ions) and 
organic degradation products are released toward the extracellular space by 
transcytosis (Salo, Lehenkari et al. 1997, Yamaki, Nakamura et al. 2005). 
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1.1.4.2 Bone remodeling compartment (BRC) 
 As mentioned above, endosteal lining cells serve as a border between 
bone surface and the marrow space. This lining cell barrier persists during bone 
remodeling but is released from the cancellous bone surface by a disruption of 
the junctions between lining cells and embedded osteocytes (Hauge, Qvesel et 
al. 2001). BRC provides a ready access for regulatory factors produced outside 
bone diffusing through the canopy layer from the bloodstream to the interior of 
BRC (Eriksen, Eghbali-Fatourechi et al. 2007). In addition, this particular 
microenvironment facilitates an adequate concentration of a myriad of bone 
degradation products that promote bone formation after resorption. Therefore, 
bone lining cells would function as a selective membrane that controls the traffic 
of different substances inside BRC creating a restricted and proper milieu for the 
recruitment of osteogenic precursors. 
 The relevance of the cellular and molecular events occurring during bone 
remodeling is that under normal conditions osteoclast resorption is always 
followed by bone formation. In fact, previous remodeling and resorption is a 
common mechanism that takes place before the formation of mature bone 
during bone healing.  There are at least three prerequisites that must be 
accomplished before bone formation is initiated during trabecular bone 
remodeling: Bone Remodeling Compartment formation, physical and 
biochemical signals and finally osteoprogenitor cell recruitment.  
 BRC formation coincides with the initiation of bone resorption (Hauge, 
Qvesel et al. 2001).Figure 1.7. As we mention above, BRC is a space 
interposed between the bone surface undergoing remodeling and the bone 
marrow (Andersen, Sondergaard et al. 2009). Osteoid degradation and bone 
lining cell detachment from the bone surface allow the creation of a 
distinguished three dimensional space. Under the canopy formed by the 
detached lining cells, an adequate gradient concentration of soluble signals and 
other degradation products are confined. 
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Figure 1.7. Bone remodeling compartment (BRC) formation coincides with the initiation 
of bone resorption. This particular microenvironment facilitates an adequate 
concentration of a myriad of bone degradation products. Taken from (Khosla, 
Westendorf et al. 2008) 
 
 Mature osteoblasts produce an organic matrix mostly of type I collagen. 
These collagen fibrils, together with mucopolysaccharides, proteoglycans and 
other locally or distally produced molecules, form a substrate on which inorganic 
salts are deposited (Centrella, McCarthy et al. 1988). This organic and inorganic 
matrix ossifies and becomes subject to the catabolic or resorptive efforts of the 
osteoclasts (Centrella, McCarthy et al. 1988). During osteoclast resorption the 
inorganic fraction is gradually dissolved and the demineralized collagen matrix is 
not completely degraded. These organic and mineral debris are co-released 
toward the extracellular space acting as signalling molecules. 
 Polypeptide growth factors are molecules that are specialized for 
intercellular communication (Taipale and Keski-Oja 1997). These soluble 
signalling molecules (growth factors and cytokines) are produced and stored in 
the bone matrix by mature osteoblasts and released during resorption. Of note, 
these intercellular signalling proteins act in picomolar to nanomolar 
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concentrations to regulate host cell function and their physiological role is to 
coordinate the modeling and remodeling of tissues (Nathan and Sporn 1991). 
Among the main growth factor families stored in bone matrix and having 
significant effects on bone remodeling are Insulin Growth Factor (IGF), 
Transforming Growth Factor  (TGF), Platelet Derived Growth Factor (PDGF), 
Bone Morphogenetic Proteins (BMP´s), Fibroblast Growth Factor (FGF) 
(Hauschka, Mavrakos et al. 1986, Canalis, McCarthy et al. 1988). Because a 
myriad of cytokines and growth factors are stored in the bone matrix it follows 
that multiple signalling biochemical molecules are simultaneously present within 
the bone remodeling compartment. 
 Osteoclast activity causes a rise in the concentrations of calcium and 
phosphate in the aqueous solution of the BRC (Price, Caputo et al. 2002). In 
addition, this cellular activity could promote the liberation of carbonate, 
magnesium and sodium ions present in the inorganic bone component. 
However, it has been reported that a Fetuin-Matrix Gla Protein (MGP) prevents 
the growth, aggregation and precipitation of the mineral component. That is, 
MGP prevents the formation of the supersaturated concentrations of the 
released ions (Ca2+, PO43-, Mg2+,CO32-)  within the BRC that lead to formation of 
crystal nuclei (Price, Caputo et al. 2002). 
 Calcium is the major component of the mineralized bone matrix which is, 
in its ionic form, released within the remodeling microenvironment (Dvorak and 
Riccardi 2004). Calcium levels are significantly different in the hemivacuole, 
where previous studies have reported values between 8-40mM and over the 
nonresorbing surface of the osteoclast, where direct measurements indicate 
values <2mM during resorption (Berger, Rathod et al. 2001). Osteoclasts 
respond to elevated calcium concentrations inside the resorbing compartment 
with morphological and functional changes triggering a dramatic cell retraction 
followed by a profound inhibition of bone resorption (Zaidi, Shankar et al. 1995). 
In contrast, exposure of MC3T3-E1 cells (which exhibit properties of 
osteoprogenitor cells and preosteoblasts) to high amounts of calcium (up to 
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4.8mM) stimulated both chemotaxis and proliferation (Yamaguchi, 
Chattopadhyay et al. 1998). However, both events have also been reported with 
10 mM.  (González-Vázquez, Planell et al 2014) 
 Osteoprogenitor recruitment is the result of a highly organized 
combination of cell activities including migration, proliferation, differentiation and 
apoptosis (Jensen, Andersen et al. 2015). These cellular events overlap in time 
and are located spatially within the BRC and nearby anatomical structures. The 
release and solubilization of a myriad of organic and mineral degradation debris 
and their diffusion through the canopy influence the adjacent tissues. This 
diffusion induces changes on the rich capillary subendosteal region and the 
lifted canopy cells.  By these mechanisms, the BRC provides guidance to these 
progenitor cells by building up a high concentration of chemoattractans and 
through site specific anchorage (Andersen, Sondergaard et al. 2009). 
 The reversal phase couples bone resorption and bone formation by 
generating an osteogenic environment at remodeling sites (Delaisse 2014). 
Reversal cells colonize resorbed bone surfaces immediately after osteoclasts 
leave and prepare the eroded surfaces for bone formation, removing resorption 
debris left behind and depositing a cement line (Abdelgawad, Delaisse et al. 
2016). Under these conditions, the covered and particularly prepared reversal 
surfaces becomes an osteoinductive cellular coating promoting the migration of 
preosteoblasts preceding the deposition of new bone (Yamaguchi, 
Chattopadhyay et al. 1998, Delaisse 2014). 
 Kristensen etal. suggest a model in which osteoprogenitor recruitment 
may proceed along three concurrent routes: route 1 originates from BLCs and 
proceeds along the bone surface; route 2 originates from bone marrow 
envelope cells, which develop into the canopies covering the bone remodeling 
site and supply osteoblast progenitors to the reversal surfaces; route 3 probably 
originates from perivascular cells, reaching canopies along capillaries   
(Kristensen, Andersen et al. 2014). Figure 1.8. In addition, since bone 
remodeling occurs in a highly vascularized region, an alternative source has 
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been suggested. Eghbali-Fatourechi et al (2007) reported that cells destined to 
become osteoblasts on bone surfaces likely enter the BRC not directly from the 
bone marrow, but rather via the capillaries that penetrate the BRCs. These 
circulating osteoblastic cells contribute to the pool of osteoblastic cells entering 
the BRC (Eghbali-Fatourechi, Modder et al. 2007).Figure 1.9. 
 
 
Figure 1.8. Model proposing three distinct routes for recruitment of osteoprogenitor cells 
during cancellous bone remodeling. (Kristensen, Andersen et al. 2014) 
 
 
Figure 1.9. Because BRC is highly vascularized, circulating cells would be an additional 
source of osteoprogenitor cells. (Eghbali-Fatourechi, Modder et al. 2007) 
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 Considering these recruitment routes of osteoprogenitors two separate 
but complementary episodes of cellular migration could occur within BRC. First, 
reversal cells follow the released signalling molecules and attach demineralized 
collagen fibrils left by osteoclasts. Second, osteoblast precursors are attracted 
chemotactically from the canopy and perivascular areas of the capillaries toward 
the reversal surface. Consistently, expression of Smooth Muscle Actin (SMA), a 
motility marker, has been detected in pericytes around the capillaries, the BRC 
canopy and reversal cells on eroded surfaces but not in mature osteoblasts 
(Kristensen, Andersen et al. 2013, Delaisse 2014). SMA may support the 
migratory function of osteoblast progenitors because it is a contractile protein 
involved in cell motility (Kristensen, Andersen et al. 2013). In addition, the 
motility of progenitor cells gradually decreases during differentiation. At a later 
stage, the differentiated cells have low motility and high adhesion ability (Ichida, 
Yui et al. 2011).  
 Several reports have demonstrated that degradation debris such as 
collagen fragments, relatively low doses of growth factors and extracellular 
calcium ions produce a common chemotactic response on mesenchymal stem 
cells (Godwin and Soltoff 1997, Dirckx, Van Hul et al. 2013, Krause, Scadden et 
al. 2013, Abdelgawad, Soe et al. 2014). Consequently, osteoprogenitor cells at 
an early differentiation stage could be targets for chemoattractive signalling 
molecules liberated from bone matrix and such cells could gradually differentiate 
into mature bone forming osteoblasts. 
 Given that bone formation occurs only above a given cell density 
(Kristensen, Andersen et al. 2014), attraction of osteoblast progenitors toward 
the reversal surface is required. A possible mechanism for providing sufficient 
bone forming osteoblasts is cell proliferation and regions of convergence 
between capillaries and canopies coincide with a higher prevalence of Ki-67 
positive proliferative cells (Kristensen, Andersen et al. 2013). In addition, it has 
been proven that canopy cells are less differentiated than those of the reversal 
surface, as shown by the inverse levels of ki-67 versus osterix expression 
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(Kristensen, Andersen et al. 2014). Disruption or loss of canopies are 
associated with insufficient osteoblast progenitor recruitment on the reversal 
surface and absence of progression of the remodeling cycle to bone formation 
(Jensen, Andersen et al. 2015).  
 The need for a minimal cell number before cells can differentiate is also 
observed in skeletogenesis (Hall and Miyake 1992, Hall and Miyake 1995). 
Condensations represent a critical stage in skeletogenesis such that osteoblasts 
will only differentiate in high cell densities associated with condensations. 
Previously dispersed populations of mesenchymal cells gather together to 
differentiate. They form an aggregation or condensation, which is the earliest 
sign of the initiation of a skeletal element (Hall and Miyake 1992, Hall and 
Miyake 2000). Therefore, bone formation after resorption requires a cellular 
threshold which is reached by the attraction of cells from different sources in 
response to chemotactic signals toward the eroded bone surface. 
 
 
1.2  BONE REGENERATION AND BONE GRAFTS 
 
 Bone is the hardest connective tissue in the human body. However, the 
skeletal tissue can be injured by trauma, atrophied by tooth loss, incompletely 
formed during congenital craniofacial bone defects or destroyed by pathological 
conditions. Understanding the basic principles of the cellular and molecular 
events regulating osteoblast differentiation is essential for the development of 
effective approaches to regenerate bone.  
 
1.2.1 Autogenous grafts 
 Autologous bone grafts, that is bone taken from another anatomical area 
of the same patient, has been considered the “gold standard” for treating 
osseous defects. Autogenous bone are obtained with certain costs to the patient 
including additional surgical incisions; increased postoperative morbidity; 
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weakened donor bone sites; and potentially serious complications from any of 
the previous conditions (Burchardt 1983). 
  Although this approach is associated with these drawbacks, this type of 
graft merges the required features to promote bone healing and regeneration. 
Autografts agglutinate a three-dimensional bone framework, cellular secreted 
and bone matrix derived signalling molecules and osteoprogenitor-osteocyte 
lineage cells. Indeed, autologous grafts promote bone defect regeneration as 
the result of the integration of three interdependent mechanisms. Namely, 
osteogenesis, osteoconduction and osteoinduction.  
 
1.2.2 Osteogenesis, osteoconduction and osteoinduction 
 Osteogenesis occurs when viable osteoblasts and/or osteoblast 
precursors are transplanted with the bone graft. Since few mature osteoblasts 
survive transplantation the stem cells are responsible for a significant portion of 
new bone formation (Cypher and Grossman 1996). Osteoconduction is the 
mechanism through which trabecular autografts provide a three dimensional 
framework giving mechanical support and allowing the invasion of vascular and 
stromal tissue into the graft. This term means that bone growth on a surface or 
down into pores, channels or pipes (Albrektsson and Johansson 2001).  
 In this process, a bone graft serves as a scaffold or lattice, facilitating 
migration of host cells for osteogenesis and eventually leading to partial 
resorption of the graft. This process is known as creeping substitution (Lind and 
Bunger 2001). Several biomaterials have been manufactured reproducing 
specific attributes that promote bone formation. These graft substitutes are 
formed from a variety of materials that are designed to mimic the three 
dimensional characteristics of autograft (Matassi, Nistri et al. 2011). 
Osteoconduction depends to a fairly large extent on previous osteoinduction 
(Albrektsson and Johansson 2001).  
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 Osteoinduction is the guided attraction of osteoprogenitor cells from the 
host bed responding to chemoattractant signals released from the implanted 
graft or biomaterial. In addition, osteoinduction could be defined as the process 
by which osteogenesis is induced and implies the recruitment of immature cells 
and the stimulation of these cells to develop into preosteoblasts (Albrektsson 
and Johansson 2001). The mechanism of osteoinduction occurs naturally to 
varying degrees during fracture healing and after the implantation of an 
autologous bone graft and human acid demineralized bone matrix (Ferretti, 
Ripamonti et al. 2010). This process is mediated by a cascade of signals and 
the activations of several extra and intracellular receptors (Giannoudis, 
Dinopoulos et al. 2005). Among these signals regulating the osteoinductive 
process are BMPs and other growth factors such as TGF, PDGF, IGF and 
FGF (Cypher and Grossman 1996, Lind and Bunger 2001).  
 In addition, it has been shown that osteoinduction by diverse calcium 
phosphate biomaterials, such as synthetic hydroxyapatite ceramic, coral derived 
hydroxyapatite ceramic,  and tricalcium phosphate, biphasic calcium 
phosphate in various animal models (Habibovic and de Groot 2007, Barradas, 
Yuan et al. 2011). In the present day, the exact mechanism of osteoinduction by 
biomaterials is still not completely understood (Barradas, Yuan et al. 2011). The 
osteoinductive property of calcium based biomaterials induces osteoblast 
differentiation and bone formation without the addition of recombinant growth 
factors. Furthermore, it is questionable whether the mechanism of 
osteoinduction by BMPs and that of inorganic biomaterials are related and, if so, 
to what extent (Barradas, Yuan et al. 2011). At least one relevant difference in 
osteoinduction by BMPs and biomaterials is that bone formation induced by 
biomaterials starts directly as bone (intramembranous) (Yuan, Van Den Doel et 
al. 2002), while recombinant BMP induces endochondral bone in vivo (Reddi 
and Cunningham 1993, Wozney and Rosen 1998).  
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1.3 BONE TISSUE ENGINEERING  
 
 The term “tissue engineering” was officially coined at a National Science 
Foundation workshop in 1988 to mean “the application of principles and 
methods of engineering and life sciences toward the fundamental understanding 
of structure-function relationships in normal and pathological mammalian tissues 
and the development of biological substitutes to restore, maintain or improve 
tissue function” (O'Brien 2011). This definition has evolved and several key 
elements have been included. The fundamental concept behind tissue 
engineering is to utilize the body´s natural biological response to tissue damage 
in conjunction with engineering principles (Porter, Ruckh et al. 2009).  
 The following definitions have been suggested by several authors: 
 
 Tissue engineering is an interdisciplinary field that implies the principles 
 of engineering and the life sciences toward the development of biological 
 substitutes that restore, maintain or improve tissue function. (Langer and 
 Vacanti 1993). 
 
 Tissue engineering, one of the major components of regenerative 
 medicine, follows the principles of cell transplantation, materials, science 
 and engineering towards the development of biological substitutes that 
 can restore and maintain normal function (Atala 2004). 
 
 Tissue engineering is the science of design and  manufacture of new 
 tissues for the functional restoration of  the impaired organs and 
 replacement of lost parts due to disease, trauma or tumors. Tissue 
 engineering is based on principles of cellular and molecular 
 developmental biology and morphogenesis guided by bioengineering 
 and biomechanics (Reddi 2000). 
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 Currently distinct anatomical zones are used to obtain autogenous bone 
grafts to reconstruct craniofacial bone defects, such as cleft palate, pathological 
conditions or after trauma. Between these sources are iliac crest, cranial bone, 
mandibular symphysis, rib and tibia (Rawashdeh and Telfah 2008). However, 
wherever bone is harvested undesirable and detrimental effects are produced at 
the donor area.  
 To avoid these drawbacks, bone tissue engineering has emerged to 
provide an alternative to autogenous bone harvesting. The three key ingredients 
for tissue engineering are inductive signals, responding cells and biomimetic 
biomaterials based on extracellular matrix (scaffolding) (Reddi 2000). Current 
efforts are aimed at developing smart three-dimensional scaffolds similar to the 
internal architecture of bone that are inherently osteoinductive by mimicking the 
geometry and biochemistry of the extracellular matrix of the tissue (Heliotis, 
Ripamonti et al. 2009).Bone tissue engineering strategies to regenerate bone 
generally fall into two categories: scaffolds seeded with cells and cell-free 
devices, which depend on the body´s natural ability to regenerate (Atala 2004, 
Bueno and Glowacki 2009). 
 The cell-based approaches require the isolation, culture and expansion 
of mesenchymal stem cells. These osteogenic progenitor cells are seeded into 
the scaffold and induced to differentiate into bone forming osteoblasts. This 
differentiation is promoted through an osteogenic media or a single recombinant 
growth factor or in combination. Finally, seeded scaffolds are implanted in the 
injured zone to regenerate the bone tissue.  
 In Contrast, cell-free or acellular approaches do not depend on 
previously isolated mesenchymal stem cells. Essentially, it is dependent on the 
body´s natural ability to regenerate and on the presence of the host´s 
osteoprogenitor cells (Atala 2004, Bueno and Glowacki 2009). The scaffolds 
gradually degrade upon implantation and are replaced and remodeled by new 
bone synthesized and secreted by ingrowing cells (Bueno and Glowacki 2009).  
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Since acellular scaffolds provide a three dimensional framework, they are 
frequently combined with soluble growth factors to promote osteogenic cells and 
vessel ingrowth. By combining osteoconductive and osteoinductive materials as 
composites, the aim is to achieve better material properties (Schieker, Seitz et 
al. 2006).  
 Therefore, tissue engineering constructs promote bone regeneration by 
the combination of a three dimensional provisional scaffold with osteoinductive 
signals, with or without cells. This construct allows mesenchymal stem cells to 
migrate from the host recipient site and attach to its surface, proliferate and 
differentiate into bone matrix secreting osteoblasts. 
 
 
 
1.3.1 Mesenchymal Stem Cells (MSCs) 
 The concept of stem cells originated at the end of the19th century as a 
theoretical postulate to account for the ability of certain tissues to self-renew for 
the lifetime of an organism  (Bianco, Robey et al. 2008). Stem cells are cells 
with the capacity for unlimited or prolonged self-renewal. Usually, between the 
stem cells and their terminally differentiated progeny, there is an intermediate 
population of committed progenitors with limited proliferative capacity and 
restricted differentiation potential (Watt and Hogan 2000). Figure 1.10. MSCs 
are pluripotent cells present in many adult mesenchymal tissues, such as 
synovium, muscle, adipose tissue and bone marrow (Jorgensen, Gordeladze et 
al. 2004). However, it has been reported that MSCs could reside in virtually all 
post-natal organs and tissues related to their existence in a perivascular niche 
or blood vessel walls (Caplan 2008, Crisan, Yap et al. 2008).   
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Figure 1.10. Mesenchymal stem cells have the potential to differentiate in multiple 
tissues. Taken from (Dimarino, Caplan et al. 2013) 
 
 MSCs in bone marrow are a source of osteoblast progenitors. They are 
part of the stromal population supporting hematopoiesis as well as contributing 
to the structural organization as an integral component of the sinusoidal walls 
(Sacchetti, Funari et al. 2007, Bianco, Robey et al. 2008).A minimal criteria for 
the identification of human MSCs has been established. First, MSC´s must be 
plastic-adherent. Second, MSCs must express specific surface antigen CD105, 
CD73 and CD90. Third, they must have multipotent differentiation potential 
(Dominici, Le Blanc et al. 2006). Table 1.1. 
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Table 1.1.Minimal criteria to define human MSC´s. Taken from (Dominici, Le Blanc et al. 
2006) 
 
 
 Skeletal development in the embryo, repair and remodeling in the adult 
require the direct contribution of mesenchymal stem cells. The gradual 
progression in the differentiation sequence into bone involves several 
overlapping stages. Figure 1.11. Progression from one stage to the next 
depends on the presence of specific local bioactive factors from surrounding 
cells (paracrine regulation), signals emitted by the cell itself (autocrine 
regulation) as well as other environmental cues (Caplan 1991, Bruder, Fink et 
al. 1994).The sum of these various intrinsic and extrinsic signals defines the 
developmental position of the cells (Caplan 1991). 
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Figure 1.11. During skeletal development exists an intimate relationship between 
vasculature and newly forming bone. Taken from (Caplan 1991) 
 
 
 Adult MSCs in vivo function to supply replacement units for the 
differentiated cells that naturally expire or reservoirs for the regeneration of 
tissues after injury or disease (Caplan 2005, da Silva Meirelles, Chagastelles et 
al. 2006). This process of stem cell-generated replacement decreases with age 
after reaching its peak in the mid to late 20s in humans (Caplan 2005).Since 
mesenchymal stem cells are present in concentrations of less than 1 in 
100,000-500,000 nucleated cells in bone marrow aspirates from adults, the 
MSCs must be culture expanded to obtain sufficient numbers for clinical use 
(Caplan 2005).  In addition, MSC frequency seems to decline with age, from 
1/10,000 nucleated cells in a newborn to about 1/1,000,000 nucleated marrow 
cells in an 80 year-old person (Caplan 1994). Figure 1.12. 
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Figure 1.12. Decrease in MSC´s titers between newborn and 80 year old. 
Taken from (Caplan 2007) 
 
 According to these data, the regenerative ability of bone could be inverse 
to age in humans. In addition, as it has been mentioned above, a deficiency in 
the appropriate initial cell density could be detrimental in the sequence of bone 
formation. Although they can be managed safely during a standard ex vivo 
expansion period (6-8 weeks), human MSC can undergo spontaneous 
transformation following long-term in vitro culture (4-5 months) (Rubio, Garcia-
Castro et al. 2005).This ex vivo amplification of MSCs may lead to malignant 
transformation in mice, where extensive passaging leads to cytogenetic 
aberrations (Charbord 2010). 
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1.3.2 Scaffold 
 
 A scaffold is a provisional three-dimensional structure that defines the 
area where osteogenic cells will produce bone. It has been suggested 
(Schieker, Seitz et al. 2006, Porter, Ruckh et al. 2009, Matassi, Nistri et al. 
2011) that ideally, biomaterials used as scaffolds for bone tissue engineering 
should meet several design criteria: 
 
 -Scaffolds must favor cellular attachment, growth and differentiation.  
 
 -Deliver bioactive molecules to accelerate healing and prevent 
 pathology. 
 
 -Scaffolds should be biocompatible, with lack of immunogenic response. 
 
 -Scaffolds should be biodegradable and eventually eliminated and 
 produce non-toxic degradation products. 
 
 -Porosity should be high enough to provide sufficient space for cell 
 adhesion and extracellular matrix regeneration. The porous 
 architecture must allow vascularization and bone ingrowth. 
 
 -The material should be reproducibly processable into three
 dimensional structures. The material must be able to be sterilized 
 without loss of bioactivity. 
 
 - It must provide temporary mechanical support. It is important to design 
 a matrix that possesses mechanical properties similar to the tissue in the 
 immediate surrounding area of the defect. 
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1.3.3 Signals 
  
1.3.3.1 Bone Morphogenetic Proteins (BMPs) 
 One of the earliest reports about the treatment of calvarial bone defects 
was made for Nicholas Seen in 1889 (Senn,1889). He used implantations of 
decalcified bone after trephining dog’s skull. Decalcification and disinfection of 
bone was performed by keeping the prepared tissue in dilute muriatic acid 
(Hydrochloric Acid). Sixty five years later, Marshall Urist discovered that 
intramuscular implantation of demineralized bone matrix was able to produce 
bone and bone marrow as final product. Decalcified bone was replaced by new 
bone tissue very rapidly over a period of several weeks by a mechanism called 
bone formation by autoinduction (Urist 1965). 
  The osteogenic effect was associated with the organic component of 
bone. The active component was identified as being proteinaceous and named 
bone morphogenetic protein (BMP) (Wozney and Rosen 1998). In the1980s 
Sampath and Reddi made a fundamental contribution to the description of the 
mechanism of action of demineralized bone matrix. Approximately 3% of the 
proteins were solubilized from demineralized bone matrix and the remaining 
residue was mainly insoluble type I bone collagen. The soluble extract alone or 
the insoluble residue alone was incapable of new bone formation. However, the 
addition of the extract to the insoluble collagen and its subsequent implantation 
resulted in bone induction. Optimal osteogenic activity in this case was a 
collaboration between soluble extract and the insoluble collagenous substratum 
(Sampath and Reddi 1981, Reddi 2000, Reddi 2000).  
 BMP concentration in demineralized bone matrix was in the range of 1-2 
g. That is, a few micrograms of osteogenic proteins were isolated from over a 
ton of bovine bone (Reddi 2005). This limitation led to the cloning and 
recombination of BMPs in 1988 (Wozney and Rosen 1998). With this, large 
amounts of recombinant proteins were available for clinical application. Then, 
demineralized bone matrix was the original source for discovery of several key  
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growth factors that were subsequently cloned and recombinantly expressed to 
become FDA approved clinical therapeutic proteins (Gruskin, Doll et al. 2012). 
 BMPs are proteins produced by cells and secreted as ligands to act as 
autocrine or paracrine signals. Initially, they were identified as bone 
osteoinductive factors, but currently, we know they are involved in a myriad of 
biological activities. BMPs are a subclass of molecules of the TGF superfamily 
and as members of this family they initiate signalling by binding to type I and II 
Serine/Threonine Kinase receptors. To date, over 20 BMP family members have 
been isolated and characterized. BMP-1 through BMP-7 are expressed in 
skeletal tissue and BMP-2, -4 and -6 are the most readily detectable BMPs in 
osteoblast cultures (Gazzerro and Canalis 2006). 
 BMPs transduce signals through Smad and non-Smad signalling 
pathways(Miyazono, Kamiya et al. 2010). Figure 1.13. BMP target genes 
include a growing number of osteoblast-determining transcription factors such 
as Runx2, Osterix and Dlx3/5 (Ulsamer, Ortuno et al. 2008, Ortuno, Ruiz-Gaspa 
et al. 2010). Smads are proteins that mediate the TGFand BMP responses. The 
Smads can be classified in 3 different groups: R-Smad, Co-Smad and I-Smad. 
The receptor mediated Smad proteins (R-Smad) include Smad1, Smad2, 
Smad3, Smad5 and Smad8. They function in ligand specific pathways and are 
phosphorylated at the C-terminus upon transmembrane receptor kinase 
activation (Chacko, Qin et al. 2001). Smad1, Smad5 and Smad8 transduce 
signalling from BMP ligands whereas Smad2 and Smad3 from TGFC-terminal 
phosphorylation of R-Smad leads to the recruitment of Smad4 (Co-Smad) and 
the formation of active signalling complexes (Chacko, Qin et al. 2001). 
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Figure 1.13. BMP´s activate Smad and non-Smad signalling pathways. 
Taken from (Beederman, Lamplot et al. 2013) 
 
  In addition to these positively acting Smads, the inhibitory Smads (I-
Smads), Smad6 and Smad7, antagonize signalling by interacting with the 
receptor complex to prevent access and phosphorylation of R-Smad or by 
interfering with R-Smad/Smad4 complexing (Wrana and Attisano 2000). In 
addition, BMP effects can be regulated at different levels including:  
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 -Inhibition of BMP-BMP receptor interaction by extracellular BMP binding 
 proteins. 
 
 -Presence of dominant negative non-signalling membrane
 pseudoreceptors. 
 
 - Blocking of BMP signalling by inhibitory Smads. 
 
 -Blocking of BMP signalling by intracellular Smad binding  proteins. 
 
 -Ubiquination and proteosomal degradation of BMP signalling effectors 
 (Gazzerro and Canalis 2006). 
  
 This BMP/Smad signalling is one of the most prominent pathways 
promoting osteoblast differentiation. However, binding of BMPs also induces the 
activation of other signalling cascades. Smad independent pathways include 
ERK 1/2, p38, PI3K/AKT and -catenin dependent signalling (Ghosh-
Choudhury, Abboud et al. 2003, Lee, Lim et al. 2009, Sieber, Kopf et al. 2009, 
Gamez, Rodriguez-Carballo et al. 2016).  
 The efficacy of BMPs to regenerate bone in animal models and several 
applications in the clinical context are well known: bone fracture healing (Lane, 
Yasko et al. 1999, Vaccaro, Anderson et al. 2002, Axelrad and Einhorn 2009), 
alveolar cleft defects (Dickinson, Ashley et al. 2008), spinal fusion (Minamide, 
Yoshida et al. 2005) and defects in craniofacial bones (Yuan, Cao et al. 2012). 
 As a result, medical use of BMP-2 and BMP-7 was FDA approved for 
specific osteoinductive applications. However, most studies of bone 
regeneration in animal models make use of supra-physiological doses of BMPs. 
More importantly, BMP therapy in clinical practice also employs high amounts of 
BMPs, ranging between 1.5-3.3 mg (1.5 mg BMP-2, or 3.3mg BMP-7), even 
though in some cases, only minimal tissue regeneration is induced (Ripamonti 
2010). Reports have demonstrated the safety of BMPs (White, Vaccaro et al. 
2007). Nonetheless, some adverse effects have been documented with these 
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high doses of clinical BMP treatments(Carragee, Hurwitz et al. 2011). That is, 
BMPs when used in supraphysiological doses can stimulate bone resorption 
and turnover, eliciting a counterproductive response rather than achieving the 
intended objective of bone formation (Nakashima and Reddi 2003). 
 BMP is an expensive medication, adding anywhere from $5,000 to 
$15,000 to the cost of treatment, and its prescription is officially restricted to 
certain situations (Einhorn 2010, Courvoisier, Sailhan et al. 2014).This limited 
approval suggest that the FDA is only mildly impressed with its efficacy (Einhorn 
2010).Then, an alternative to overcome the current shortcomings of high doses 
of BMPs is the combination of cellular and molecular approaches to enhance 
osteogenic differentiation and bone formation with lower amounts of growth 
factors. 
 
 
1.3.3.2 Wnt 
 
 Wnt are lipid modified glycoproteins secreted by cells as signalling 
molecules. They act primarily over short ranges to control stem cell behavior 
(Yang, Wang et al. 2016). In 1982 Roel Nusse reported the identification of Int-1 
protooncogene now known as Wnt-1 (acronym from wingless and Int-1, Wnt-1) 
(Nusse and Varmus 1982, Niehrs 2012). Currently, 19 human Wnt proteins are 
known and research evidence highlights the relevance of wnt signalling in bone 
development and regeneration. Wnts have historically been classified as 
“canonical” Wnt-1, Wnt3a, Wnt-8 and Wnt-10b or as “non-canonical” Wnt-4, 
Wnt-5a and Wnt-11 but these simplistic classifications are now being challenged 
(Hoeppner, Secreto et al. 2009).  
 Mesenchymal stem cells (MSCs) have a self-renewal and multilineage 
differentiation potential (Sarugaser, Hanoun et al. 2009).Wnt signalling proteins 
modulate self-renewal (Reya, Duncan et al. 2003, Willert, Brown et al. 2003, 
Morrell, Leucht et al. 2008) and multipotential differentiation of these progenitor 
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cells. Binding of Wnt ligands to their cognate receptors in MSCs promotes 
osteoblast differentiation over the chondrogenic lineage (Day, Guo et al. 2005, 
Hill, Spater et al. 2005) and prevent the commitment to adipocytes by 
suppressing PPAR(Bennett, Longo et al. 2005, Kang, Bennett et al. 2007). 
Figure 1.14.  
 
 
Figure 1.14.Wnt promotes osteoblast differentiation and prevent adipocyte or 
chondrogenic differentiation. Taken from (Kawai, Modder et al. 2011) 
 
 
 Wnt proteins and BMPs share the ability of activating the osteogenic 
transcription factors Runx2, Osterix and Dlx5 (Bennett, Longo et al. 2005, Kang, 
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Bennett et al. 2007, Ulsamer, Ortuno et al. 2008, Ortuno, Ruiz-Gaspa et al. 
2010), but both Wnt and BMPs bind to different membrane receptors. In 
addition, as it was mentioned above, BMP-2 treatment induces endochondral 
ossification whereas the same injuries treated with liposomal Wnt heal via 
intramembranous ossification (Minear, Leucht et al. 2010). However, a cross-
talk between both pathways has been reported extensively (Nakashima, Katagiri 
et al. 2005, Itasaki and Hoppler 2010, Rodriguez-Carballo, Ulsamer et al. 2011, 
Zhang, Oyajobi et al. 2013). Figure 1.15. 
 
 
Figure 1.15.Wnt participates in multiple stages of osteoblast differentiation. Taken from 
(Hoeppner, Secreto et al. 2009) 
 
 Wnt ligands bind to Frizzled as well as LRP5/6 receptors. After Wnt 
receptors are activated three different pathways can be triggered, the canonical 
Wnt/catenin pathway, the Wnt/Ca2+ pathway (both the most relevant Wnt 
pathways for osteoblast differentiation) and Planar Cell Polarity (PCP). Wnt-3a 
is a representative ligand that activates the catenin dependent pathway or 
canonical Wnt signalling (Komekado, Yamamoto et al. 2007). Cells constantly 
synthesize catenin but in the absence of Wnt ligand receptor activation it is 
degraded. This degradation is through the incorporation of catenin into the 
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destruction complex. The destruction complex is a multiprotein assembly, but its 
core components include, in addition to catenin itself, glycogen synthase 
kinase 3 (GSK3) and CK1, the scaffolding protein Axin, the adenomatous 
polyposis coli (APC) protein and TrCPand PP2A (Stamos and Weis 2013). 
 After activation of Wnt signalling an inhibition of catenin degradation is 
produced. Figure 1.16. This stabilization of catenin levels is either through the 
inactivation of the destruction complex by promoting the degradation of the 
scaffold protein Axin (Lee, Salic et al. 2003, Cselenyi, Jernigan et al. 2008) or by 
glycogen synthase kinase-3GSK3inhibition activity by Dishevelled 
(Malbon 2005). 


Figure 1.16.  Without Wnt ligands -catenin is degradated.  
Taken from (Kubota, Michigami et al. 2010)  
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 Dishevelled is required for Wnt dependent inhibition of the degradation 
complex (Yokoyama, Yin et al. 2007). Therefore, in the presence of the Wnt 
signalling the activated Dishevelled binds to Axin and inhibits catenin 
phosphorylation and the consequent degradation by GSK3 
 Regarding non canonical Wnt pathways, a distinctive attribute of 
Wnt/Ca2+ signalling is the release and elevation of intracellular calcium 
concentrations. Wnt ligands such as Wnt-5a and Wnt-11 trigger calcium 
release. However, Wnt-3a has been reported to activate both the catenin 
dependent canonical pathway and the Ca2+/CaMKII noncanonical pathways 
(Nalesso, Sherwood et al. 2011). 
 Kestler and Kühl (2011) identified a concentration dependent activation 
of Wnt pathways. Figure 1.17.Wnt/catenin signalling is activated by high 
concentrations of Wnt ligands. In contrast, Wnt/Ca2+ signalling is favored by 
lower concentrations of Wnt ligands, mediating the activation of phospholipase 
C that generates diacylglycerol (DAG) and inositol-3,4,5 trisphosphate (IP3) 
and the consequent release of calcium ions from endoplasmic reticulum (ER). 
Both pathways reciprocally inhibit each other (Kestler and Kuhl 2011, Nalesso, 
Sherwood et al. 2011).  
 Wnt/PCP signalling controls tissue polarity and cell movement and is 
observed in an array of developmental processes involving tissue organization. 
Its disruption can lead to severe developmental defects (Katoh 2005, Bayly and 
Axelrod 2011). In addition, the non-canonical Wnt/PCP pathway plays a major 
role in neural crest migration (De Calisto, Araya et al. 2005, Mayor and 
Theveneau 2014). 
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Figure 1.17.Concentration-dependent activation of Wnt pathways.  
Taken from (Kestler and Kuhl 2011) 
 
 Currently, there is extensive research supporting the ability of BMPs to 
promote localized bone regeneration. However, BMPs cannot be delivered 
systemically and they are not available to treat osteoporosis (Hoeppner, Secreto 
et al. 2009). In contrast, Wnts for local bone regeneration have not been directly 
tested because of practical difficulties in purifying and administering the highly 
hydrophobic and insoluble Wnt proteins in vivo (Minear, Leucht et al. 2010). It 
has been shown that Wnt signalling increases osteoblast differentiation, bone 
formation and bone mass by the stabilization and accumulation of catenin. 
This increased bone mass by GSK3 inhibition results in an early temporal 
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amplification of MSCs which are driven to osteoblast differentiation at the 
expense of adipogenesis (Gambardella, Nagaraju et al. 2011). 
  Features of aging bone or osteoporosis are reduced osteoblast 
differentiation, increased osteoclastic resorption, decreased bone mineral 
density, as well as increased adipose tissue. Wnt signalling has been 
associated with aging effects on bone. In fact, decreased gene expression of 
various Wnt related proteins, as well as Wnt co-receptors and Wnt inhibitors, is 
downregulated in the bone tissue of aged mice (Rauner, Sipos et al. 2008). 
Figure 1.18. 
  In addition, decreased osteoblast differentiation and bone formation 
during aging and osteoporosis are the result of enhanced adipogenesis versus 
osteoblastogenesis from precursor cells (Justesen, Stenderup et al. 2001, 
Rauner, Sipos et al. 2008). With aging, there is a change in bone marrow 
composition increasing the volume of adipose tissue associated with an 
imbalance between augmented osteoclast activity and declined osteoblast bone 
formation, resulting in osteoporosis (Justesen, Stenderup et al. 2001, Verma, 
Rajaratnam et al. 2002, Rosen and Bouxsein 2006). 
 
 
Figure 1.18. Expression of various Wnt related genes is downregulated with age in 
mice. Taken from (Rauner, Sipos et al. 2008). 
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 Wnt regulation is a tightly controlled mechanism which is predominantly 
driven by two antagonists, Sclerostin (SOST) and DKK1 (Rossini, Gatti et al. 
2013). Two basic therapeutic strategies for enhancing bone regeneration 
through Wnt signalling exist: adding agonists or blocking naturally occurring 
antagonists (Hoeppner, Secreto et al. 2009). Since Wnt receptors are 
expressed in multiple cell types, the use of Wnt agonists are considerably 
unspecific and more selective targets are needed. Sclerostin is an inhibitor of 
bone formation and is expressed by all three terminally differentiated cell types 
embedded within mineralized matrices: osteocytes, cementocytes and 
hypertrophic chondrocytes (van Bezooijen, Bronckers et al. 2009). 
  Because SOST is an inhibitor of osteoblast differentiation and Wnt 
signalling, antagonists of SOST have been considered as potential therapeutic 
targets to treat osteoporosis. In addition, they have also been considered in 
promoting bone regeneration by systemic administration. Pharmacologic 
inhibition of SOST using a Sclerostin neutralizing monoclonal antibody has been 
used after placement of titanium implants (Virdi, Irish et al. 2015), to reconstruct 
large defects due to periodontitis in rats (Taut, Jin et al. 2013), in healing of 
proximal tibial defects in ovariectomized rats (McDonald, Morse et al. 2012) and 
to treat osteoporosis using a rat model (Li, Niu et al. 2014). In every case, an 
enhancement of bone-implant contact and increased levels of bone formation 
were obtained. 
 
 
1.3.3.3 Calcium  
 The skeletal tissue is the largest reserve of minerals in the human body 
and almost all the calcium is stored in bones. After bone resorption by 
osteoclasts, the mineral component is dissolved and calcium ions are released 
first within the immediate remodeling microenvironment and then toward the 
circulation. This localized elevation in the extracellular calcium concentration 
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induces cellular and molecular effects on the responding osteoprogenitor cells. 
Therefore, there is an exchange of calcium ions between blood and bone and 
calcium can be transferred into and out of the bone by two independent 
mechanisms (requiring the activity of osteoclasts and osteoblasts) (Parfitt 1989). 
 In bone, extracellular ionic calcium concentration, a major extracellular 
factor in the bone microenvironment during bone remodeling, could potentially 
serve as an extracellular first messenger, acting via Calcium Sensing Receptor 
(CaR) (Brown and MacLeod 2001, Chattopadhyay, Yano et al. 2004). This 
Calcium Sensing Receptor (CaR) regulates four relevant cellular processes 
decisive for MSC´s fate: migration, proliferation, differentiation and apoptosis 
(Godwin and Soltoff 1997, Yamaguchi, Chattopadhyay et al. 1998, Yamaguchi, 
Chattopadhyay et al. 2000, Brown and MacLeod 2001, Chattopadhyay, Yano et 
al. 2004, Dvorak, Siddiqua et al. 2004, González-Vázquez, Planell et al 2014  et 
al 2014).  
 It has been reported that during in vivo resorption, the levels of 
extracellular ionized calcium are < 2mM over the non-resorbing surface of 
osteoclasts (Berger, Rathod et al. 2001).Thus, this localized elevation in 
extracellular calcium concentrations could serve as cues that initiate the 
sequence of osteoblast differentiation. 
 In 1993 Brown et al. reported the cloning of an extracellular calcium 
sensing receptor (CaR) from bovine parathyroid. The novel receptor features a 
large extracellular domain involved in calcium binding (Brown, Gamba et al. 
1993).Figure 1.19. As a GPCR, the CaR is comprised of the three main 
structural features of this receptor family: an extracellular domain, a seven 
transmembrane domain and an intracellular tail (Magno, Ward et al. 2011). The 
function of the receptor could be divided by the plasma membrane into an 
extracellular component (“sensor”) and an intracellular component (“transmitter”) 
(Magno, Ward et al. 2011). 
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Figure 1.19. Structure of Calcium sensing Receptor (CaR). Taken from 
(Brown, Gamba et al. 1993) 
 
 The sensory aspect of the CaR relates to its ability to detect changes in 
the extracellular environment through binding its agonists, whereas the 
transmitter characteristics of the receptor relate to its ability to modulate 
intracellular signalling events (Magno, Ward et al. 2011). Figure 1.20. Because 
the extracellular domain of CaR contains highly concentrated regions of 
negative charge, a characteristic shared by many of the diverse agonists which 
activate CaR is a high concentration of positive charge (Breitwieser, Miedlich et 
al. 2004). 
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Figure 1.20. After Ca2+binds to the extracellular domain IP3 and DAG are activated by 
PLC. Taken from (Mascia, Denning et al. 2012) 
 
 Cells at rest have a Ca2+ concentration of 100nM but are activated when 
this level rises to roughly 1000nM (Berridge, Lipp et al. 2000). This elevation in 
the cytosolic calcium concentration is observed after extracellular calcium and 
growth factors bind to their cognate receptors. BMP (Mandal, Das et al. 2016), 
Wnt (Slusarski, Yang-Snyder et al. 1997), VEGF (Hamdollah Zadeh, Glass et al. 
2008), PDGF (Tucker, Chang et al. 1989), and EGF (Moolenaar, Aerts et al. 
1986), mediate this rapid and transient intracellular Ca2+ increment. Mobilization 
of ions from extracellular sources crossing the surface membrane and from the 
endoplasmic reticulum contribute to this increased cytosolic calcium levels.  
 The Ca2+ signalling network can be divided into four functional units: 
 - Signalling is triggered by a stimulus that generates various Ca2+ 
 mobilizing signals. 
 - ON activation mechanisms that feed Ca2+into the  cytoplasm. 
 - Ca2+functions as a messenger to stimulate numerous Ca2+ sensitive
 processes. Figure 1.21. 
 - OFF mechanisms that removes Ca2+ from the cytoplasm. 
 (Berridge, Lipp et al. 2000). 
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 Extracellular Ca2+binding to CaR activates phospholipase C (PLC) and 
produces inositol 1,4,5 trisphosphate (IP3) and diacylglycerol (DAG). IP3 
promotes calcium release endoplasmic reticulum whereas DAG activates 
protein kinase C (PKC). This initiates an intricate intracellular network including 
but not limited to ERK 1/2, p38, Smad, PI3K/AKT and GSK3(Dvorak and 
Riccardi 2004, Dvorak, Siddiqua et al. 2004, Leclerc, Neant et al. 2011). 
 In addition, Daub et al reported an activation of MAPK pathway by G 
protein coupled receptor (GPCR) through intracellular signal crosstalk, by a 
transactivation mechanism (Daub, Weiss et al. 1996). Therefore, extracellular 
calcium as ligand induces its own intracellular release and strengthens its signal 
by intermingling with other intracellular inputs. 
 
 
 
Figure 1.21. Ca2+interact with many other signalling pathways. Taken from 
(Berridge, Lipp et al. 2000) 
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2. CHAPTER II: AIMS 
 
 
 
[Cada capítol  ha de començar en pàgina imparell] 
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AIM 1: 
To select an optimized three dimensional scaffold by evaluating the effects of 
gelatin and CaSO4 on MSC differentiation into osteoblasts using in vitro and in 
vivo models.  
 
 
AIM 2: 
To evaluate the interaction of BMP-2 and Wnt-3a on MSCs differentiation into 
osteoblasts in vitro, after 24 hours and after 10 days, and in vivo after five 
weeks using the selected three-dimensional (3D) scaffold. 
 
 
AIM 3: 
To identify the molecular mechanisms through which extracellular calcium and 
BMP-2 interact in the short- (24 hours) and long-term (10 days). 
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3. CHAPTER III: MATERIALS AND METHODS 
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Bone Marrow Mesenchymal Stem Cells (BMMSC´s) isolation and culture 
 
 BMMSCs were isolated from femurs of 6-8 week old BALB/c mice.  Mice 
were euthanized by CO2 and femurs were dissected. Next, the skin and muscle 
were cleaned and conserved in complete media (DMEM supplemented with 
10% FBS, penicillin/streptomycin, 1mM pyruvate and 2mM glutamine). Femur 
ends were cut using a Rongeaur. Then, 1 milliliter syringe with a 26 gauge 
needle attached was filled with warmed Media. Next, the marrow was flushed 
and collected in a 50 ml Falcon. The cell solution was resuspended several 
times by pipetting and finally filtered with a 70 µm cell strainer (Falcon, USA).   
 The filtered cell solution was transferred to a 100 mm cell culture plate 
and incubated to 37o. Media was changed 24 hours later and then each 8 hours 
for 2-3 days to discard non- adherent cells. Approximately between 5-7 days the 
adherent cells reach 75-80% of confluence. 
  At this time, attached cells were washed three times with warmed PBS 
and tripsinized for 3 minutes at room temperature.  Lifted cells were recultured 
and expanded for future experiments. 
 
Protocol for freezing cells (Cryopreservation) 
- Identify the cryotubs with the cell type, date of freezing, name of the 
researcher.  - Eliminate the medium and wash twice with warm PBS. Eliminate 
PBS and add 1 ml of trypsin and wait between 3-5 minutes.  
- Using a 15 ml Falcon with 3 ml of 10% DMEM, recover the trypsin/cells 
solution and centrifuge at 1200 rpm for 5 minutes. 
- Eliminate the supernadant and keep the cell pellet.  Resuspend the pellet with 
900 l with 10% DMEM gently.  
- Transfer the cell solution to the labeled cryotube and add 100 l of DMSO.  
 - Wrap the cryotube using a piece of paper towel and then with aluminium foil.       
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- Place the cryotube/s into the -800 C. After 24 hours transfer the cryotube/s into 
the liquid nitrogen tank. 
 
 
2D gelatin coated and 3D gelatin Scaffold Preparation 
 
 To prepare 2D gelatin coated cell culture plates, 12 well plates surfaces 
were coated with a thin layer of 0.1% gelatin/PBS solution mixed with CaSO4 
dissolved in media at different concentrations ( 3, 5, 7.5, 10 mM).  Plastic 
surfaces coated just with gelatin solution were used as controls.  Plate wells 
were filled with 1.5 ml of the respective solution and were incubated overnight at 
37o C. Then, media was removed carefully and treated wells were left for 1 hour 
inside a laminar flow hood to dry the treated surfaces and then stored until their 
use. In the case of the monolayer cell culture wells respective CaSO4 
concentrations were added without gelatin. Finally, the cells were seeded. 
 To prepare a 3D scaffold we used a 1mm3 Gelatin sponge (Gelita, B. 
Braun). We cut the sponges to obtain slices of 1mm thickness using a surgical 
blade No. 11 attached to a scalpel handle. For the in vivo experiment 2mm 
slices were used. Next a new middle cut was made and of this way we acquired 
a 10x5x1mm scaffold. Before seeding under sterile conditions, these scaffolds 
were soaked using a 100 mm cell culture plate with 7 ml of complete media or 
PBS and incubated for 12-24 hours.  At that time, each soaked gelatin scaffold 
was placed in the bottom of a 1.5 ml microcentrifuge tube and the excess of 
media was absorbed by pipetting.  BMMSC´s were detached by trypsin and 
collected by centrifugation (1500-1700 rpm for 5 minutes).  The cell pellet was 
resuspended with a final volume of complete media according to the number of 
scaffold/well replicates of each condition of study (calculate 20 µl of Media and 
2x105 cells for each scaffold).  
 Finally, the volume of the cell solution was added (20 µl containing 2x105 
cells) to the gelatin scaffold in the microcentrifuge tube and incubated in vertical 
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position for 4-6 hours at 37o C. With this individual seeding we allowed cellular 
adhesion and equality in the number of cells to each scaffold.  Then, we 
carefully transferred each seeded scaffold to a well (24 well plate) and 200 µl of 
complete media were added. An important issue is to avoid that the seeded 
scaffold float by adding additional media at this point. After 24 hours, the media 
was removed carefully and the scaffold washed 3 times with warmed PBS.  PBS 
was aspirated with care and 200 µl of the respective condition of study were 
added. We refreshed the cultured cells with 100 µl of the corresponding 
condition each 3 days. 
 
 
 
 Extracellular calcium concentration effect on BM-MSC´s differentiation 
 
 To assess the effect of extracellular calcium on BMMSC´s differentiation 
into osteoblasts, CaSO4was used as source of calcium. Three culture models, a 
monolayer plastic surface, 2D gelatin coated and 3D gelatin scaffolds were 
used. CaSO4was dissolved in complete media and filtered under sterile 
conditions and the solution was stored as 20mM stocks at 4oC. Then, BMMSC´s 
were treated with different CaSO4concentrations from 3mM, 5mM, 7.5mM and 
10mM, using complete media as control. After 10 days, cell cultures were 
prepared for RNA isolation and RT PCR. 
 
Extracellular calcium effect inhibition by EDTA 
 BMMSC´s seeded on 3D gelatin scaffolds were cultured in the presence 
of 7.5 mM concentration of CaSO4 or CaCl2 (Sigma-Aldrich) as source of 
calcium, CaSO4+ EDTA or CaCl2 + EDTA, using complete media as control.  
EDTA was used as extracellular calcium chelator with a final concentration of 
7.5 mM from a stock of 20mM. After 10 days, cell cultures were prepared for 
RNA isolation and RT PCR. 
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Western blot assay 
 
 BM-MSCs seeded in 3D gelatin scaffolds were cultured for 24 hours or 
10 days. Cells were lysed with 75 μl of lysis buffer (PBS, 1% Triton X-100, 100 
mM PMSF, 1μg/ml pepstatin, 1 μg/ml leupeptin, 1 mM of sodium orthovanadate, 
10 mMNaF and 10mM β-glycerophosphate) for one hour at 4ºC. Thirty 
micrograms of protein samples were subjected to SDS-PAGE and 
immunoblotting. 
  Membranes were incubated with different antibodies: pGSK3α/β 
Ser9/21 (9331S), pSMAD1/5/8 Ser465/467 (9511S)and pS6 Ser235/236 (2211) 
and pp38 Thr180/Tyr182 (9211S) from Cell Signalling Technology, pErk1/2 
(M5670) from Sigma, β-catenin (610154) from BD TransductionLaboratories 
and α-tubulin (T6199) from Sigma, all diluted to a ratio of 1:1000.Horseradish 
peroxidase-conjugated secondary antibodies were used, followed by incubation 
with EZ-ECL reagent (Biological Industries). A chemiluminescent image of the 
immunoblots was captured with a Fujifilm LAS 3000 device. 
 
Separating gel 10% 
Acrylamide 40%  2.5 ml 
Lower buffer 4x  2.5 ml  
H2O Mili Q   5    ml 
APS 10%   100l 
TEMED (add last)  5    l 
Stacking gel 
Acrylamide 40%  0.525 ml 
Upper buffer 4%  1.25   ml 
H2O Mili Q   3.225 ml 
APS 10%   25     l 
TEMED (add last)  5 l 
  55
 
Calvarial critical-size bone defects and in vivo bone regeneration 
 
 A surgical procedure was performed in 10-week old male BALB/c mice. 
Animals were housed individually and fed ad libitum. All procedures were 
performed in accordance with the protocols approved by the University of 
Barcelona Animal Research Ethics Committee and the Generalitat de 
Catalunya. Animals were anesthetized with isoflurane inhalation and an 
intraperitoneal injection of buprenorphine (0.05 mg/kg) was administered to 
provide intraoperative analgesia. To expose the parietal bones, a longitudinal 
midline incision was made and the tissues retracted. A circular critical-size bone 
defect with an outer diameter of 5 mm was carried out with a trephine bur on the 
left parietal.  We cultured 4 x 105 BM-MSCs per scaffold in accordance with 
the protocol described above for 3D gelatin scaffold preparation. After cells had 
been exposed to the respective conditions for 48 hours, a 1% final concentration 
solution of low melting agarose at 36ºC was added as a bonding agent. 
Scaffolds were implanted to fill the bone defects, depending on the respective 
experimental group. The incised tissues were sutured and the animals 
monitored daily during the recovery phase. Five weeks after surgery, the 
animals were euthanized and the calvariae dissected. 
 
 
 
 
 
 
 


  56
CT analysis 
 
 Five weeks after surgery, the mice were euthanized. The heads were 
fixed with 4% paraformaldehyde for 24 h and stored in PBS/azide at 4C until 
scanning. Scanning was performed using a Skyscan 1076 High-Resolution 
scanner (Skyscan). All samples were placed horizontally in a holder, and the 
exposure parameters were 49 kV, 200 mA, with an exposure time of 500 ms 
and 180rotation. Data reconstruction was performed using the NRecon 
software. A Gaussian noise filter was applied and the three-dimensional models 
were performed with the CTAn software. Both programs were provided by the 
manufacturer. 
  A cylindrical region of interest (ROI) with a 5mm diameter was 
positioned manually to cover the bone defect area. For each sample, 375 slices 
were processed and analyzed. The ROIs were converted into volumes of 
interest that were used to quantify the extent of newly formed bone. 
 
 
 
Quantitative RT-PCR analysis 
 
 The BMMSC RNA isolation was performed using Trisure (Bioline), 
according to the manufacturer’s instructions. The RNA quantification was 
performed by spectrophotometric analysis (Nanodrop ND 1000; Thermo 
Scientific). The purified RNA (3 mg) was reverse transcribed using a High-
Capacity Retrotranscription Kit (Applied Biosystems), and50 ng of cDNA per 
reaction was used in each quantitative RT-PCR (qRT-PCR), with two replicates 
per sample. qRT PCRs were carried out using the TaqMan 5´-nuclease probe 
method (Applied Biosystems). The relative transcript expression levels were 
normalized to Gapdh expression (endogenous control). 
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Cell proliferation assays 
BMMSC proliferation was evaluated using 7-AAD and BrdU labeling (BD), 
following the manufacturer’s protocol. Briefly, 1 x 105 cells were seeded in 24-
well plates or onto scaffolds (according to the experimental groups) and 
incubated at 370Cfor 24 h. Then, BrdU (10 mM) was added to the medium for 
45min. The cells were harvested with 0.04mg/mL of liberase (Roche) for 10min 
and analyzed by flow cytometry. 
 
 
 
Histology 
 After CT image acquisition and 3D reconstruction, the calvaria samples 
were dissected and the soft tissue was removed. The dissected calvariae were 
descalcified with Decalcifier II (Leica Biosystems) for 2-3 days. Samples were 
placed in a tissue processing cassette and then dehydrated, embedded in 
paraffin and sectioned. The slides with the 5 mm sections were deparaffinized, 
rehydrated and stained. 
 
Hematoxylin and Eosin staining 
Deparaffinization 
- 30 minutes in dry oven at 60oC 
- Immerse the slides in xylene 2 minutes. 2X 
Rehydration 
- Ethanol 100% 2 min 
- Ethanol 96% 2 min 
- Ethanol 80% 2 min 
- Ethanol 70% 2 min 
- Destilled water  2 min 
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Staining 
-  Stain in hematoxylin 3 min (check the samples) 
- Wash with running tap water (use a glass staining dish) 
- Acid alcohol for   15 seconds 
- Wash with running tap water 
- Ammonia water   30 seconds 
- Wash with running tap water 
- Ethanol 70%  seconds 
- Ethanol 80%  seconds 
- Counterstain eosin 1.5 min 
- Wash using distilled water 
- Ethanol 96%  seconds 2X 
- Ethanol 100%  seconds 
- Ethanol 100%  3 min 
- Ethanol-Xylene 50% 2 min 
- Xylene   3 min 3X 
- Mount using DPX  leave to dry overnight 
 
 
Masson´s Trichrome 
-from deparaffinization and rehydration 
- Stain in Weigert`s hematoxylin 30 seconds 
- Wash with running tap water 
- Differentiate solution A  seconds 
- Wash using distilled water 3 mins 
- Ponceau solution    30 seconds 
- Differentiate solution B  seconds 
- Wash using distilled water seconds 
- Ethanol 96%   seconds 2X 
- Ethanol 100%   3 min 
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-Ethanol-Xylene 50%  2 min 
- Xylene    3mins 3X 
- Mount with DPX    leave to dry overnight 
 
 
 
Immunohistochemistry 
 
 For immunohistochemistry, the tissue samples were boiled in citrate 
buffer, washed and blocked with serum.  The primary antibodies against Osterix 
(OSX ab22522 Abcam) or GFP (ab290 Abcam) were incubated at 1:200 dilution 
on the sections overnight. After washing, the samples were incubated with a 
biotinylated secondary antibody (1:100) and streptavidin –horseradish 
peroxidase (1:400) for 1 hour. The sections were incubated with 
diaminobenzidine and H2O2and counterstained with hematoxylin. 
 
 
 
 
Statistical analyses 
The statistical analyses were performed using Student’st-test with the GraphPad 
Prism 5 software. The quantitative data are presented as the mean – standard 
error of the mean. The differences were considered significant at p-values of 
<0.05, with *p < 0.05, **p < 0.01, and ***p < 0.001. 
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4 CHAPTER IV: RESULTS 
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AIM 1:  
GELATIN/CaSO4 SCAFFOLD AS THREE-DIMENSIONAL (3D) CELL 
CULTURE SYSTEM 
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4.1.1 Extracellular calcium increases osteogenic gene expression in BM-
MSCs cultured in 3D gelatin scaffolds 
 
 In order to evaluate the influence of the culture system on the osteoblast 
differentiation of BM-MSCs, we compared three different culture models: 
untreated plastic surface, 2D gelatin-coated surface and 3D gelatin scaffold. 
Cells seeded on 3D gelatin scaffolds showed greater upregulation of all 
osteogenic markers evaluated (Alpl p< 0.001; Osteocalcin p< 0.001 and Osterix 
p< 0.001) than monolayers on plastic surfaces or 2D gelatin coated plates. 
Figure 4.1.1 
 
Figure 4.1.1 Three dimensional Gelatin/CaSO4 scaffolds increase osteoblast gene 
expression. 
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 This result suggests that 3D gelatin scaffolds promote higher osteoblast 
differentiation than plastic or 2D gelatin-coated surfaces. We then assessed 
whether extracellular Ca2+ could have a beneficial effect on osteoblast 
differentiation. We evaluated the effects of different Ca2+ concentrations on BM-
MSCs using the three culture systems described above. Higher expressions of 
Alpl, Osteocalcin and Osterix were obtained using Ca2+ concentrations from 
3mM to 10mM. Figure 4.1.2 
 A concentration of 7.5mM was optimal for the late osteogenic 
differentiation markers Osteocalcin and Osterix. Taken together, these results 
suggest that extracellular Ca2+ concentrations of between 3mM and 10mM 
produce a beneficial effect on the expression of Osteocalcin and Osterix, 
regardless of the culture model used. We confirmed the specificity of these 
effects by comparing CaSO4 and CaCl2 as calcium ion sources or by chelating 
Ca2+ with EDTA. Both CaSO4 and CaCl2 stimulated the expression of 
osteogenic markers. Moreover, the addition of EDTA completely blocked the 
positive effects of CaSO4 and CaCl2 on gene expression. Figure 4.1.3 
 
 
4.1.2 A composite gelatin/CaSO4 scaffold increases osteogenic gene 
expression in vitro. 
 In addition to growth factors, another challenge for bone regeneration is 
to find the optimal matrix for BMMSC transplantation and their osteogenic 
differentiation. We evaluated the influence of gelatin and biphasic CaSO4 alone 
or in combination on BMMSC morphology, proliferation and osteogenic marker 
expression in vitro. Since the BMMSCs used in this study were obtained from 
transgenic GFP-expressing BALB/c mice, we could easily visualize these cells 
in the scaffolds.  
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 Images revealed morphological differences between the evaluated 
seeding conditions, taking a monolayer plastic surface as control. Cells seeded 
on the control monolayer display a flattened morphology without intracellular 
vesicles whereas those adhered to CaSO4 crystals in a 2D plastic surface 
revealed an increased number and size of intracellular vesicles.  BMMSCs  
 
Figure 4.1.2 Extracellular Ca2+induce osteoblast gene expression. 
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Figure 4.1.3 EDTA inhibits the osteogenic effect of extracellular Ca2+. 
 
 
grown on gelatin substrata were connected to each other by cytoplasmic 
prolongations in a marked reticular pattern according to the three dimensional 
structure of the sponge. Figure 4.1.4 
 Next, we examined the ability of these scaffolds to maintain the 
undifferentiated status of BMMSCs. Quantification of the gene expression of 
stemness markers Oct4 and Nanog (Tsai, Su et al. 2012, Han, Han et al. 2014), 
demonstrate that gelatin sponge did not modify expression of Nanog or Oct4 
after 24 hours of culture. Interestingly, after long term culture on the scaffolds 
(10 days), expression of Oct4 and Nanog significantly decreased when 
BMMSCs were cultured on the gelatin plus CaSO4 scaffold. Addition of the 
osteogenic cytokine BMP-2 induced a slight decrease of stemness in most of 
the conditions analyzed. A parallel analysis of osteoblast-determining 
transcription factors showed no major differences in the expression of Runx2 in 
either short or long term cultures.  
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Figure 4.1.4 Green fluorescent protein (GFP) expressing MSCs cultured in different 
substrates for 24 hours. 
  
 
 Noteworthy, when cells were cultured in the gelatin plus CaSO4 
scaffolds, expression of Osx was significantly increased at both 24 hours and 10 
days of culture. Figure 4.1.5. Addition of BMP-2 also induced increased 
expression of Osx after 10 days irrespective of the substrata employed.  
 We further analyzed proliferation of BMMSCs cultured in the different 
biomaterials for 24 hours by flow cytometry by labeling DNA with 7-AAD and 
BrdU incorporation. The results are in agreement with expression of the 
stemness markers, showing higher proliferative rate in gelatin or gelatin plus 
CaSO4 scaffolds as measured by BrdU incorporation or percentage of cells in S 
or G2/M phases of the cell cycle. Figure 4.1.6. Altogether, these results suggest 
that this composite scaffold allows an early expansion of the BMMSCs at short 
times, which is followed by increased osteogenic differentiation after long-term 
culture.  
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Figure 4.1.5 Effect of the gelatin/CaSO4 scaffold on stemness and osteogenic marker 
expression in BMMSCs. Data presented as the mean of three independent experiments. 
*p < 0.05, **p < 0.01, ***p < 0.001. 
 
 
 
Figure 4.1.6 FACS analysis of 7-AAD labeling (left) and BrdU incorporation (right) of 
BMMSCs cultured in the indicated scaffold. Data presented as the mean of three 
independent experiments. *p < 0.05, **p < 0.01,***p < 0.001. 
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4.1.3 Gelatin/CaSO4 scaffold improves bone formation in vivo. 
  In order to verify these observations in bone regeneration we analyzed 
their ability to heal a criitical-size calvarial bone defect. We implanted the 
composite scaffold in the absence and presence of cells in a 5mm size calvarial 
defect (Cooper, Mooney et al. 2010). Defects of this diameter are unable to heal 
by themselves (Cooper, Mooney et al. 2010, Gomes and Fernandes 2011). 
Furthermore, we used a minimal irrigation during the surgical procedure for a 
more challenging cranial defect (Sawyer, Song et al. 2009). This was also 
proven in our model by the lack of bone formation in empty defects. Instead the 
defects were partially filled with a layer of fibrous tissue. After 5 weeks of 
scaffold implantation, bone formation was analyzed by μCT to evaluate new 
bone formation. Figure 4.1.7. 
 
Figure 4.1.7 Microcomputed tomography quantification of bone regeneration of the 
gelatin/CaSO4 scaffold implants.*p < 0.05.
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Figure 4.1.8 Masson’s trichrome staining of representative calvarial sections of each 
group. 4X scale bar, 1000 m. 10X scale bar,400 m. 20X scale bar,200 m.  
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 The analysis of reconstructed images demonstrated that the 
gelatin/CaSO4 scaffold seeded with BMMSCs had the greatest bone 
regeneration potential, as seen in the margins of the calvarial defects when 
compared to the other conditions assessed. Furthermore, these data shows that 
bone formation arises from the function of the implanted exogenous cells, since 
implantation of the scaffold by itself only promoted marginal effects on bone 
formation.  
 Histological analysis confirmed the findings obtained by μCT. Very 
limited bone formation was observed in control defects implanted only with 
agarose. Of note, when only the scaffold (gelatin plus CaSO4) without cells was 
implanted, abundant endogenous cellular invasion was observed. However and 
more important, when BMMSCs in the composite scaffold were implanted, 
significant bone healing was obtained accompanied by a more mature structure. 
These data indicate that BMMSCs in combination with a composite 
gelatin/CaSO4 scaffold are able to partially recover a defect that otherwise would 
not heal in these adult mice (Gomes and Fernandes 2011). Figure 4.1.8. 
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AIM 2:  
BMP-2 AND Wnt3A INCREASE OSTEOBLAST DIFFERENTIATION 
AND BONE FORMATION USING A GELATIN/CaSO4 SCAFFOLD  
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4.2.1 Wnt3a cooperates with BMP-2 increasing the expression of 
osteoblastic markers. 
 
Among the extra-cellular signals involved in the induction of the 
osteoblast phenotype, BMP and Wnt families of morphogens are essential for 
the commitment and differentiation of the osteoblast lineage (Tsumaki and 
Yoshikawa 2005, Hoeppner, Secreto et al. 2009, Regard, Zhong et al. 2012). 
Moreover, our group has shown that both signalling pathways have cooperative 
effects on the induction of osteogenesis (Rodriguez-Carballo, Ulsamer et al. 
2011). We thus hypothesized that combination of the two osteogenic signals 
could lead to improved bone regeneration. 
 We cultured BMMSCs in the composite scaffold for 24 hours and then 
for further 24 hours or 10 days in the presence of BMP-2 and/or Wnt3a. We first 
assessed the expression of the stemness markers Oct4 and Nanog. Oct4 and 
Nanog expression were strongly activated by Wnt3a addition after 24 hours, 
whereas BMP-2 had no major effects. However, after 10 days, Nanog 
expression was strongly down-regulated when both BMP-2 and Wnt3a were 
added together. 
 In order to further assess the cooperative effect between Wnt3a and 
BMP-2, we also evaluated the expression of Col1a1, Runx2 and Osx. Wnt3a 
alone or in combination with BMP-2 induced the expression of Col1a1 at 24 
hours. Figure 4.2.2. Moreover, stimulation with both cytokines conferred a 
strong and significant additive effect on the expression of Runx2 and Osx after 
24 hours. Interestingly synergic effects were maintained after 10 days of culture 
for Col1a1 and Osx mRNA expression. Cell cycle and BrdU analysis of their 
proliferation rate of cells treated with these cytokines for 24 hours were also in 
agreement with expression of the stemness markers. Addition of Wnt3a 
increased growth rate in parallel to Oct4 and Nanog expression, whereas BMP- 
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2 did not had major influences in proliferation or stemness marker expression. 
Figure 4.2.1. These results support the concept of collaboration between BMP 
and Wnt3a signalling in enhancing osteogenesis of BMMSCs in the cultured 
scaffold ex-vivo. 
 
 
 
 
 
 
 
Figure 4.2.1 FACS analysis of 7-AAD labeling (left) and BrdU incorporation (right) of the 
BMMSCs cultured with the indicated cytokines for 24 h. Data presented as the mean 
±standard error of the mean (SEM) of three independent experiments. *p < 0.05, **p < 
0.01, ***p < 0.001. 
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Figure 4.2.2 BMP-2 and Wnt3a addition increases osteoblast marker expression. (A) 
Expression levels of Oct4 and Nanog assessed at 24 h or 10 days of culture while being 
treated with the indicated cytokines. (B) Expression levels of Col1a1, Runx2, and Osx 
assessed at 24 h or 10 days of culture while being treated with the indicated cytokines. 
The mRNAs were normalized to Gapdh and four independent experiments were 
performed. 
 
 
4.2.2 Wnt3a and BMP-2 cooperatively enhance bone regeneration in vivo. 
 To assess whether combination of Wnt3a and BMP-2 increases bone 
regeneration in vivo, we implanted a gelatin/CaSO4 scaffold seeded with 
BMMSCs pre-treated ex-vivo with BMP-2 and/or Wnt3a for 24 hours pre-
implantation. Critical-size defects in calvarial bone were implanted with cultured 
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scaffolds using agarose as a gelling agent. After 5 weeks of the implantation, we 
evaluated the regenerated bone by a μCT scan and the outcomes presented as 
percentages (BV/TV) of the healed area. Representative images of the three-
dimensional reconstructions are shown in Figure 4.2.3. Mineralized bone 
extending from the rims of the defect was significantly increased scaffolds were 
pre-treated with BMP-2 or BMP-2 and Wnt3a. Histological analysis revealed 
different characteristics in the regenerated bone. Figure 4.2.4. The volume of 
new bone formation was significantly greater in Wnt3a/BMP-2-treated implants.  
Moreover, bone structure was also more mature in Wnt3a/BMP-2 implants in 
comparison to the other treatment groups.  
 
 
Figure 4.2.3 Representative images of reconstructions 
of the calvarial defects treated with the described conditions. 
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Figure 4.2.4 Masson’s trichrome staining of representative calvarial sections of each 
group. 4X scale bar, 1000 m. 10X scale bar, 400 m. 20X scale bar, 200 m.  
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 We also wanted to confirm the relative contribution of implanted 
BMMSCs respective to endogenous recruitment of osteoprecursors in order to 
discriminate between a direct action of BMMSCs or a paracrine effect on 
endogenous cells. Since BMMSCs were isolated from a GFP-expressing 
transgenic mice strain, expression of GFP would discriminate between 
exogenous and endogenous cells. Thus, Wnt3a/BMP-2-treated implants were 
immunostained 5 weeks after implantation. 
  To assess the specificity of the labeling, another histological section 
from the same animal was used as negative control (without primary anti-GFP 
antibody) which resulted in total absence of signal. Figure 4.2.5. A significant 
number of cells, scattered through the new bone tissue, were positively stained 
for GFP suggesting that transplanted cells survived and partially contribute to 
new bone formation. However, additional paracrine effects on endogenous cells 
should not be discarded for their contribution to bone healing.  
 
 
Figure 4.2.5 Transplanted BMMSCs revealed by anti-GFP immunohistochemistry 5 
weeks after the implantation. 
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Figure 4.2.6 Osterix (OSX) immunohistochemistry identifies osteoblasts at the implanted 
sites. Histological sections from the calvarial defects implanted with a gelatin + CaSO4 
scaffold and cells pretreated with BMP-2 and/or Wnt3a. 
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 Immunohistochemical analysis of OSX expression was also performed to 
assess whether cells that had survived after implantation also achieved 
osteogenic potential. Implants treated with Wnt3a alone displayed an increased 
cellularity but a sparse OSX staining which suggests an increased proliferative 
rate but not increased osteoblast differentiation. Figure 4.2.6. 
  BMP-2 treated scaffolds present higher expression of OSX that is also 
visible in the woven bone around the scaffold. More importantly, combination of 
BMP-2 and Wnt3a also led to an intense expression of OSX in a significant 
higher number of osteoblasts at the implant site. Altogether, these results 
suggest that ex-vivo treatment with considerably low amount of BMP-2 
combined with Wnt3a cooperatively increases osteogenic potential in vitro and 
in vivo. This represents an improvement over current growth factor delivery 
strategies and highlights the importance of assessing combinations of 
osteogenic factors in bone tissue engineering. 
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AIM 3: 
EXTRACELLULAR CALCIUM PROMOTES OSTEOBLAST 
DIFFERENTIATION AND BONE FORMATION BY AMPLIFYING BMP-2 
EFFECTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
  86
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  87
4.3.1 Cooperation of calcium and BMP-2 in osteoblast differentiation and 
bone regeneration in calvarial critical-size defects in mice. 
 
 We further evaluated whether Ca2+ would cooperate with osteoinductive 
cytokines such as BMPs. BM-MSCs were cultured in a 3D gelatin scaffold and 
stimulated with 7.5mM CaSO4 and/or BMP-2 (2nM). Incubation for 10 days with 
CaSO4 or BMP-2 alone promoted expression of all the bone markers analyzed. 
Figure 4.3.1. More importantly, although a combination of Ca2+ and BMP-2 did 
not present any additive effects on the expression of the early osteogenic 
marker Alpl, they produced a significant additive effect on the expression of 
Osteocalcin, Runx2 and Osterix.  
 
 
 
 
 
Figure 4.3.1 Extracellular calcium increases the effects of BMP-2 on osteogenic marker 
expression. 
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Figure 4.3.2 Extracellular calcium increases the effects of BMP-2 on bone regeneration 
in vivo. 
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 Thus, when added to culture media, Ca2+ exerts a cooperative action 
with BMP-2 on late osteogenic marker expression. To extend our in vitro results 
on the cooperation between Ca2+ and BMPs to an in vivo context, we analyzed 
bone formation in calvarial critical-size bone defects in mice. Five-millimeter 
defects were performed in parietal bones and further implanted with BM-MSCs 
previously seeded in 3D gelatin scaffolds and pre-treated for 48 hours with 
either 7.5mM CaSO4 or 2nM BMP-2 alone or combined. After five weeks, skulls 
were retrieved and analyzed for bone formation in the defect. Hematoxylin/eosin 
and Masson’s trichrome stains showed dense connective tissue but no major 
bone formation in the control group. 
  Higher levels of mineralization and bone maturation were found in those 
implants treated with CaSO4, and even greater bone formation took place when 
implants were pre-treated in combination with BMP-2. Figure 4.3.2. Moreover, a 
combination of CaSO4 and BMP-2 led to a new, more mature bone structure. 
Both osteoblast and osteocytes can be observed in these bone regeneration 
areas. 
 
 
 
4.3.2 Signalling pathways involved in the cooperation of calcium and BMP-
2 during osteogenesis of BM-MSCs 
 
 To determine the mechanisms of cooperation between extracellular 
calcium and BMP-2 in BM-MSCs differentiation, we analyzed intracellular 
signalling triggered by both signalling molecules at early and late differentiation 
points. Early analysis was performed 24 hours after CaSO4 and/or BMP-2 
stimulation. As expected, BMP-2 promoted phosphorylation of SMAD1/5 and 
increased the levels of phosphorylated ERK1/2. Figure 4.3.3. By contrast, p38 
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and S6-kinase (S6K) signalling pathways were activated when cells were 
treated with Ca2+ alone. It is worth noting that, at this initial differentiation stage, 
an antagonistic effect on each signalling pathways was obtained when Ca2+ was 
added together with BMP-2. 
 
 
   A 
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 B 
 
Figure 4.3.3 Early effects of extracellular calcium on cell signalling. A.The influence of 
extracellular calcium and/or BMP-2 on major signalling pathways was evaluated. Cells 
were cultured in 3D gelatin scaffolds with Ca2+ (7.5mM) and/or BMP-2 (2nM) for 24 
hours and extracts analyzed by Western blot. B. Data was quantified from three 
independent experiments. 
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 The same intracellular components were subsequently assessed after 
treatment with a combination of CaSO4 and/or BMP-2 for 10 days. A significant 
additive or cooperative effect between Ca2+ and BMP-2 was observed on the 
phosphorylation levels of SMAD1/5 (Ser463-465), S6 (Ser235-236), GSK3 β 
(Ser9) and the total levels of β-CATENIN. Figure 4.3.4. Phosphorylation at Ser9 
of GSK3 β is mediated by AKT and results in the inhibition of its β-CATENIN 
repression action.  
 Thus, these results suggest that extracellular calcium produces a 
differential time-dependent effect on BMP-2 and AKT signalling. A signalling 
network antagonistic to BMP-2 is activated early on, whereas Ca2+ promotes a 
cooperative effect on several intracellular signalling events later on. 
 
 A 
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Figure 4.3.4 Late effects of extracellular calcium on cell signalling. A.The influence of 
extracellular calcium and/or BMP-2 on major signalling pathways at a later time point,10 
days. B.Data from three independent experiments were quantified relative to the levels 
of α-TUBULIN. Quantifications are shown as means ± SEM. Differences were 
considered significant at p values: * p < 0.05, ** p < 0.01, and ***p < 0.001 when 
compared to control and # p < 0.05, ## p < 0.01, and ###p < 0.001 when compared to 
cells treated with BMP-2 and CaSO4. 
B 
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4.3.3 Extracellular calcium promotes endogenous secreted BMP-2 and 
BMP-4 mRNA expression 
 
 After 10 days of differentiation, BM-MSCs stimulated with calcium alone 
showed activation of the SMAD1/5 pathway. Figure 4.3.4. Since there is no 
evidence that calcium activates BMP receptors directly, it could be suggested 
that the increased availability of BMP receptor ligands was responsible. We 
therefore hypothesized that, once these cells are committed to the osteoblast 
lineage, Ca2+ induces cells to secrete endogenous factors that reinforce 
differentiation through an autocrine/paracrine mechanism. 
 We assayed whether Ca2+ induced BMP-2 or BMP-4 expression. 
BMMSCs cultured in 3D gelatin scaffolds were exposed to CaSO4 
concentrations (from 3mM to 10mM) for 10 days. An increase, which reached its 
maximum at 7.5mM, was obtained for both Bmp2 and Bmp4 mRNA expression. 
Figure 4.3.5. In addition, we also determined the mRNA levels of Fgf21 (a 
tyrosine kinase receptor ligand) that inhibits osteoblastogenesis (Wei, Dutchak 
et al., 2012) and Axin2 (a target of the Wnt/β-CATENIN pathway downstream of 
GSK3). A significant increase in Axin2 expression was found, in line with Bmp2 
and Bmp4 mRNA expression. By contrast, Fgf21 mRNA expression was only 
slightly elevated, without any dose-response effect. Taken together, these 
results demonstrate that BM-MSCs stimulated with Ca2+ secrete higher levels of 
multiple critical cytokines that amplify their osteoblastic differentiation response. 
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Figure 4.3.5 Extracellular calcium induces Bmp2, Bmp4, Fgf21 and Axin2 mRNA 
expression. 
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5. CHAPTER V: DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  98
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  99
 The clinical use of supra-physiological amounts of BMP-2 to induce bone 
formation can produce several side effects. In order to propose an alternative 
and to avoid these drawbacks, we considered that BMP-2 and Wnt3a, acting 
cooperatively, could reduce the required doses and produce similar therapeutic 
effects. In our study, an optimized gelatin/CaSO4 scaffold was used to seed and 
expand BMMSCs that were pretreated ex-vivo with low doses of BMP-2 (2nM) 
and Wnt3a (50ng/ml). Based on osteogenic gene expression, μCT analysis, 
histological and immunohistochemistry data, we demonstrate that pretreatment 
of BMMSCs with a combination of BMP-2 and Wnt3a results in greater bone 
regeneration in vivo and increased osteogenic gene expression in vitro.  
 Efficient bone tissue engineering requires three components: 
biocompatible scaffolding materials, osteoblast progenitors and potent 
osteogenic cytokines. First, we directed our efforts to identify an optimal scaffold 
for BMMSC engraftment, expansion and further osteoblast specification. We 
took advantage of a composite scaffold made by a gelatin sponge with porous 
structure, incorporating biphasic CaSO4. The Biosafety and biodegradation 
activity of gelatin has been demonstrated (Kohara and Tabata 2011). Moreover, 
biphasic CaSO4 also has known osteoinductive activity with the rapid resorption 
time of only a few weeks (Grabowski and Cornett 2013). In turn, the released 
Ca2+ ions stimulate osteoblast differentiation of the osteoprogenitors on the 
scaffold and are further converted into hydroxyapatite by osteogenic cells 
(Barrere, van Blitterswijk et al. 2006, Chai, Roberts et al. 2012). Our finding that 
the culture of BMMSCs in three dimensional gelatin scaffolds increase their 
stemness and expansion is in agreement with previous reports (Atari, Caballe-
Serrano et al. 2012, Han, Zhao et al. 2012). Moreover, these effects, mediated 
by the gelatin substrata are improved in terms of growth rate as well as Oct4 
and Nanog expression by the addition of CaSO4 in the composite biomaterial. 
Stemness maintenance during the steps of biomaterial engineering is essential 
for BMMSC expansion, self-renewal and ability to further differentiate into 
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osteoblasts later (Tsai, Su et al. 2012, Han, Han et al. 2014). A rationale exists 
for the addition of exogenous BM-MSC for bone regeneration. BMMSCs could 
contribute directly to the repair process by their differentiation into osteoblasts. 
We found that exogenous GFP-expressing cells survived and integrated into the 
healed bone area and were able to differentiate into OSX-expressing cells. 
Moreover, addition of cells, either in gelatin alone or in the composite scaffold, 
enhanced in vivo regeneration in higher extension than the composite scaffold 
alone.  
 Thus, it can be suggested that in our calvarial healing model exogenous 
transplanted cells directly contribute to new bone formation. Survival of 
transplanted cells is highly dependent on a correct nutrient and oxygen supply 
(Dupont, Sharma et al. 2010, Grayson, Bunnell et al. 2015). However, even in 
the case of lower survival rates for long periods in areas of low vascularization, 
addition of BMMSCs has proven to be beneficial. Transplanted cells support 
recruitment and activation of endogenous stem cells by paracrine effects and 
dampen the action of pro-inflammatory cytokines (Caplan and Dennis 2006, Liu, 
Wang et al. 2011, Gao, Usas et al. 2014). Our data show that the addition of 
BMMSCs also increases the recruitment of GFP-negative endogenous cells in 
the new bone tissue that collaborate in the healing process.  
 BMPs and Wnts seem to have a very relevant role in mesenchymal stem 
cell self-renewal and specification towards the osteogenic lineages (Chen, Zhao 
et al. 2004, Hoeppner, Secreto et al. 2009). During embryonic development, 
Wnts and BMPs are expressed, especially in the places of bone and cartilage 
formation. Also, the addition of high doses of BMPs constitutes an ongoing 
therapy in bone regeneration and bone-tissue engineering (Ripamonti 2010). In 
our study, we demonstrate that considerably low doses of BMP-2 (as low as 
2nM) and Wnt3a (50ng/ml) display strong cooperation for osteogenic marker 
expression in vitro and bone regeneration in vivo.  
 This approach could be an alternative to the supra-physiologycal 
amounts of BMP-2 used clinically and at the same time an alternative to 
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autologous bone graft. These high doses display some off-target adverse 
effects and have been shown to also activate osteoclastic resorptive activity 
(Boerckel, Kolambkar et al. 2011, Kim, Oh et al. 2014). Moreover, our design 
based on ex-vivo pre-conditioning prior to implantation in the calvarial defect 
does not involve any kind of gene therapy, as reported in previous models of 
BMP or Wnt stimulation of BMMSCs (Shui, Zhang et al. 2014, Zhang, Wang et 
al. 2015). We hypothesized that pre-conditioning by BMP-2 and Wnt3a would be 
sufficient to trigger osteogenic responses based in several facts: (1) the 
systemic half-life of BMP-2 is of minutes and even when administered locally in 
collagen sponges, their effects soon vanished (Poynton and Lane 2002).(2) 
BMP2 activity is mostly required during the initial steps of fracture healing (Tsuji, 
Bandyopadhyay et al. 2006). (3)Wnt signalling and osteogenic capacity decline 
with age and the addition of exogenous Wnt3a restores osteogenic capacity 
(Jing, Smith et al. 2015).(4) the addition of BMP2 and Wnt3a to BMMSCs for 24 
hours is sufficient to cooperatively induce the osteoblast-specific transcription 
factors (Dlx3, Dlx5, Msx2, Runx2 and Osx) at high levels (Rodriguez-Carballo, 
Ulsamer et al. 2011).  
 Cultured scaffolds pre-treated with Wnt3a alone or in combination with 
BMP-2 resulted in an early increase in cell proliferation and Oct4 and Nanog 
gene expression. However, as seen with the scaffold assay, the opposite effect 
in Oct4 and Noggin gene expression was observed at 10 days. This apparently 
contradictory outcome is in agreement with the progression of BMMSC 
differentiation into the osteoblastic lineage. Proliferation is confined to the initial 
culture period. Once a sufficient population of progenitor cells has been 
generated, cells decelerate their proliferation and differentiate into osteoblast 
(Lin and Hankenson 2011). Minear et al. reported that Wnt3a stimulates skeletal 
stem cell proliferation and that the bone promoting effects of Wnt3a are 
achieved via this proliferative effect (Minear, Leucht et al. 2010). Moreover, this 
considerably low dose of BMP-2 (2nM) could also be mitogenic together with 
Wnt3a (Lysdahl, Baatrup et al. 2014). 
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 This initial burst of BMP-2 and Wnt3a proliferation could increase the 
later osteoblast marker expression in vitro and bone formation in vivo. The 
coordinated effect that we obtained in our model points to the existence of a 
close interrelationship between these pathways (Lin and Hankenson 2011). 
Canonical Wnt signalling is required for BMP-2 induced bone formation in 
vivo(Chen, Whetstone et al. 2007). Previous studies revealed that glycogen 
synthase kinase-3 (GSK3), the target of Wnt signalling, interferes with BMP 
signalling (Fuentealba, Eivers et al. 2007, Sapkota, Alarcon et al. 2007). GSK3 
phosphorylation is essential for the SMAD1 polyubiquitinylation by the SMURF 
E3 ubiquitin ligases (Murakami, Watabe et al. 2003, Fuentealba, Eivers et al. 
2007, Chong, Lin et al. 2010). Taking into account the central role of GSK3 in 
both BMP-2 and Wnt signalling and the fact that known specific inhibitors of that 
kinase are available (Krause, Harris et al. 2010), combination of BMP2 and 
these inhibitors could also be envisaged. 
 Different anatomical zones are used to obtain autogenous bone grafts in 
reconstructing bone defects. These sources include the iliac crest, cranial bone, 
mandibular symphysis, rib and tibia (Rawashdeh and Telfah, 2008). However, 
drawbacks include limited availability and morbidity at the donor site. To 
overcome these disadvantages, numerous tissue engineering approaches have 
been developed to take advantage of physiological osteoinductive signals 
(Henkel, Woodruff et al. 2013). Both Ca2+ and BMP-2 are known to be co-
released into the extracellular space by osteoclasts after bone matrix resorption. 
Our hypothesis was that extracellular Ca2+signals interact with BMP and lead to 
higher osteoblast differentiation and bone formation from BM-MSCs. Here, early 
and late osteogenic marker expression and histological assessment of bone 
regeneration in a calvarial critical-size defect model demonstrated that 
extracellular Ca2+ enhances the effects of BMP-2 on Osteocalcin, Runx2 and 
Osterix expression and promotes bone regeneration in vivo.  
 More importantly, mechanistically, both osteoinductors combined 
cooperate to increase long-term activation of SMAD and AKT signalling. 
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Osteogenic gene expression was significantly higher when extracellular Ca2+ 
was added, regardless of the cell culture system used. MG63 osteoblastic cells, 
both in monolayer culture and 3D gelatin hydrogels, have been reported to show 
significant mineralization when cultured with 8mM Ca2+ (Takagishi, Kawakami et 
al. 2006). Moreover, BMMSCs treated simultaneously with two different sources 
of Ca2+, CaSO4 and CaCl2, with or without EDTA, demonstrated that the 
osteogenic effect was specific for Ca2+. This outcome is consistent with the 
EGTA inhibition of osteocalcin secretion (Moreau, Aubin et al. 1997) and 
BAPTA, an intracellular Ca2+ chelator, in the response of osteoblasts to 
extracellular calcium (Danciu, Adam et al. 2003).  
 Osteoinductive factors released from resident cells or after osteoclast 
bone resorption regulate the recruitment and differentiation of osteoblastic 
progenitor cells. The binding of BMPs to their cognate receptors triggers 
canonical Smad and Smad independent pathways, including ERK, p38 and 
PI3K/AKT signalling (Sieber, Kopf et al. 2009, Gamez, Rodriguez-Carballo et al. 
2014). Several authors have reported that CaSR activation by extracellular Ca2+ 
also activates these same pathways (Danciu et al., 2003; Dvorak and Riccardi, 
2004; Riccardi, Finney et al., 2009).  
 We found that both calcium and BMP-2 induce activation of common 
signalling components, but in a differential time-dependent response. An early 
antagonistic effect between Ca2+ and BMP-2 signalling was demonstrated. This 
contrasting effect is consistent with previous reports showing a crosstalk 
between calcium signalling and the BMP pathway in which high intracellular 
calcium inhibits BMP signalling (Leclerc, Neant et al. 2011). Furthermore, 
Ca2+/calmodulin dependent kinase II (CAMKII), a primary transducer of calcium 
ions, directly interacts with Smads and antagonizes their function (Wicks, Lui et 
al. 2000). This reverse effect could be reinforced when we also consider that 
MAPK signalling inhibits BMP signals at the level of SMAD1 (Kretzschmar, 
Doody et al. 1999). Osteoblast differentiation is a multistep cascade of gene 
expression that initially supports proliferation and survival (Lefebvre and 
  104
Bhattaram 2010). The early prominent proliferative and pro-survival role of the 
MAPK and AKT/S6K network could induce the enlargement of the osteogenic 
progenitor pool (Dvorak and Riccardi, 2004).  
 
 
Figure 5.1.1 Model of the early Ca2+ effect on BMP/Smad signalling. An intracellular 
network antagonistic to Smad1 is activated. 
 
 
 
 However, when late differentiation events were analyzed, Ca2+ and BMP-
2 were found to cooperatively stimulate osteoblast differentiation through the 
strengthening of specific osteogenic signalling pathways. Increases in the 
phosphorylation of SMAD1/5, S6, GSK3 β and expression of β-CATENIN were 
consistent with the significantly higher expression of Osteocalcin, Runx2 and 
Osterix and the greater bone formation in vivo (Rodriguez-Carballo, Ulsamer et 
al. 2011, Gamez, Rodriguez-Carballo et al. 2016). Cooperative crosstalk 
between Ca2+ and BMP-2 in osteoblasts through the induction of the calcium-
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dependent transcription factor NFATc1 by BMP-2 has also been described 
recently (Mandal, Das et al. 2016). NFAT transcription factors have proved 
necessary for osteoblast differentiation and bone formation (Koga, Matsui et al. 
2005). Mechanistically, NFAT transcription factors activate osteogenesis 
through their interaction with OSX and their ability to stimulate Wnt/β-CATENIN 
signalling (Koga, Matsui et al. 2005, Fromigue, Hay et al. 2010). Unexpectedly, 
cell cultures exposed to Ca2+ alone for 10 days displayed significantly higher 
SMAD signalling. This observation correlated with the increase in Bmp2, Bmp4 
and Axin2 gene expression. BM-MSCs, periodontal ligament cells and dental 
pulp cells exposed to calcium-derived biomaterials have been reported to 
induce the upregulation of Bmp2 mRNA expression (Maeda, Nakano et al. 
2010, Barradas, Fernandes et al. 2012, Tang, Peng et al. 2014). These studies 
implicated MAPK activity and AP-1 transcription factors in such effects (Tada, 
Nemoto et al. 2010, Barradas, Fernandes et al. 2012).  
 Thus, our data support the suggestion that calcium induces an 
autocrine/paracrine loop by endogenous BMP upregulation. Furthermore, Axin2 
(a target gene of Wnt/ β-CATENIN signalling downstream of GSK3 β) was also 
expressed in long-term cell cultures. Our group recently showed that PI3K/AKT 
activity is relevant in bone formation in vivo and leads to the activation of 
SMAD1/5 and GSK3 β / β-CATENIN signalling (Gamez, Rodriguez et al., 2016). 
Several reports have demonstrated the synergistic interaction and the 
significance between BMP and Wnt during osteoblast differentiation and bone 
formation in vitro and in vivo (Rodriguez-Carballo, Ulsamer et al. 2011, Aquino-
Martinez, Rodriguez-Carballo et al. 2016). Taken together, our results 
demonstrate a delayed calcium signalling effect that likely integrates and 
reinforces an osteogenic programme from multiple inputs.  
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Figure 5.1.2 Model of the late Ca2+ effect on BMP/Smad signalling. An 
autocrine/paracrine mechanism reinforce the initial BMP-2 effect. 
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6. CHAPTER VI: CONCLUSIONS 
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1- The combination of extracellular Ca2+ signalling and a gelatin scaffold 
promotes higher osteoblast differentiation in vitro and bone formation in vivo 
compared to Ca2+ or gelatin alone. 
 
2- Low doses of BMP-2 and Wnt-3a additively increase osteoblast differentiation 
and bone regeneration using a gelatin/CaSO4 scaffold as a 3D cell culture 
system. 
 
3- Extracellular Ca2+ modulates the osteogenic effect of BMP-2. Early on, Ca2+ 
activates an intracellular network that inhibits BMP/Smad signalling. In contrast, 
it later induces an autocrine/paracrine mechanism that reinforces the osteogenic 
output. 
 
4- Mesenchymal stem cells seeded in a gelatin scaffold with CaSO4 treated ex 
vivo with a combination of BMP-2 and Wnt3a could improve bone tissue 
engineering and Ca2+ as a signal is an inexpensive and useful approach to 
regenerate bone defects. 
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